var data={"title":"Perioperative uses of intravenous opioids in adults","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Perioperative uses of intravenous opioids in adults</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/contributors\" class=\"contributor contributor_credentials\">Elizabeth Casserly, PharmD, BCPS</a></dd><dd><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/contributors\" class=\"contributor contributor_credentials\">John C Alexander, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/contributors\" class=\"contributor contributor_credentials\">Girish P Joshi, MB, BS, MD, FFARCSI</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/contributors\" class=\"contributor contributor_credentials\">Nancy A Nussmeier, MD, FAHA</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 16, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1944728715\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intravenous (IV) opioids are commonly used to provide analgesia and supplement sedation during general anesthesia or monitored anesthesia care (MAC), and are the most widely used agents for treatment of acute pain in the immediate postoperative period.</p><p>Opioids selected for perioperative use bind primarily to mu receptors in the central nervous system to produce excellent analgesia, as well as respiratory depression, miosis, and euphoria. Opioid binding to mu receptors in the peripheral nervous system produces additional effects such as cough suppression (bronchial receptors) and opioid-induced constipation (intestinal receptors). (See <a href=\"topic.htm?path=opioid-use-disorder-epidemiology-pharmacology-clinical-manifestations-course-screening-assessment-and-diagnosis#H134294956\" class=\"medical medical_review\">&quot;Opioid use disorder: Epidemiology, pharmacology, clinical manifestations, course, screening, assessment, and diagnosis&quot;, section on 'Mechanism of action'</a>.)</p><p>This topic will review perioperative uses, benefits, and adverse effects of IV opioid agents. Topics that review use of opioids in other settings (eg, critical care, palliative care, chronic pain management) are available elsewhere:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pain-control-in-the-critically-ill-adult-patient#H230414638\" class=\"medical medical_review\">&quot;Pain control in the critically ill adult patient&quot;, section on 'Opioid analgesics'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pain-assessment-and-management-in-the-last-weeks-of-life\" class=\"medical medical_review\">&quot;Pain assessment and management in the last weeks of life&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=use-of-opioids-in-the-management-of-chronic-non-cancer-pain\" class=\"medical medical_review\">&quot;Use of opioids in the management of chronic non-cancer pain&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2754072954\"><span class=\"h1\">BENEFITS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following effects of intravenous (IV) opioid agents make them useful during the perioperative period:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Effective analgesia [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Synergistic effects occur with coadministration of anesthetic or adjuvant agents from other pharmacologic classes (eg, sedative-hypnotics such as <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, benzodiazepines, inhalation anesthetics), allowing dose reduction of these agents [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/2-12\" class=\"abstract_t\">2-12</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Attenuation of autonomic responses to noxious stimuli that would otherwise result in tachycardia and hypertension [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/12-17\" class=\"abstract_t\">12-17</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Blunting of the cough and gag reflexes during manipulation of the airway (eg, laryngoscopy, intubation, or fiberoptic bronchoscopy) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/18-20\" class=\"abstract_t\">18-20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduction of pain caused by injection of IV sedative-hypnotics (eg, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a>) or muscle relaxants (eg, <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">rocuronium</a>). Optimal pain reduction is achieved by coadministering IV opioid with an IV local anesthetic, or by pre-administering IV opioid and local anesthetic with a venous occlusion technique (eg, a rubber tourniquet on the patient&rsquo;s arm) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/21-23\" class=\"abstract_t\">21-23</a>].</p><p/><p class=\"headingAnchor\" id=\"H4025963507\"><span class=\"h1\">PREVENTION AND MANAGEMENT OF ADVERSE EFFECTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intravenous (IV) opioids have potential adverse side effects that can generally be prevented or treated. Higher opioid doses are associated with greater length of hospital stay, overall cost of care, and in-hospital cardiopulmonary complications including arrest [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/24-28\" class=\"abstract_t\">24-28</a>]. </p><p>Since opioid-related adverse events are dose-dependent, multimodal opioid-sparing strategies that reduce opioid requirements are desirable. For example, protocols for early recovery after surgery (ERAS) emphasize avoidance of nausea, constipation, and ileus by limiting opioid dosing [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/29-33\" class=\"abstract_t\">29-33</a>]. Perioperative alternatives include use of regional analgesia; nonopioid analgesics, such as <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">acetaminophen</a>, nonsteroidal anti-inflammatory drugs (NSAIDs), or cyclooxygenase (COX)-2 specific inhibitors; and adjuvant agents with analgesic properties (eg, <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a>) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/34,35\" class=\"abstract_t\">34,35</a>]. Other medications that may reduce opioid requirements in the perioperative period include alpha-2 adrenergic receptor agonists such as <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> or <a href=\"topic.htm?path=clonidine-drug-information\" class=\"drug drug_general\">clonidine</a> [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/36,37\" class=\"abstract_t\">36,37</a>], and beta-adrenergic receptor antagonists such as <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a> [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/38\" class=\"abstract_t\">38</a>]. (See <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H85613\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Therapeutic options'</a> and <a href=\"topic.htm?path=pain-control-in-the-critically-ill-adult-patient#H406085831\" class=\"medical medical_review\">&quot;Pain control in the critically ill adult patient&quot;, section on 'Tolerance, withdrawal, and hyperalgesia'</a>.)</p><p>Specific adverse effects of IV opioids include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exacerbation of hypotensive effects of sedative-hypnotics (eg, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, inhalation agents) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/9-11\" class=\"abstract_t\">9-11</a>]. Thus, opioid doses are reduced or avoided in hemodynamically unstable patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Respiratory depression <span class=\"nowrap\">and/or</span> apnea. During the intraoperative period, this may be a disadvantage in a spontaneously breathing patient or may delay time to tracheal extubation. Also, respiratory depression may lead to pulmonary complications in the postoperative period [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/39-43\" class=\"abstract_t\">39-43</a>]. Thus, opioid doses are reduced if other agents that may cause respiratory depression are also administered. (See <a href=\"topic.htm?path=respiratory-problems-in-the-post-anesthesia-care-unit-pacu#H671530049\" class=\"medical medical_review\">&quot;Respiratory problems in the post-anesthesia care unit (PACU)&quot;, section on 'Opioids and anesthetic agents'</a>.)</p><p/><p class=\"bulletIndent1\">If significant hypoventilation occurs in a spontaneously breathing patient during monitored anesthesia care (MAC) or in the post-anesthesia care unit (PACU) after opioid administration, initial treatment is frequent stimulation to encourage adequate ventilation. Occasionally it is necessary to employ temporary positive pressure ventilation or to titrate low doses of IV <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> (eg, 4 to 40 mcg). Careful titration of these naloxone doses typically reverses opioid effects safely, while preserving some analgesia. Rarely, the sudden reversal of analgesia causes a sympathetic surge with resultant hypertension, tachycardia, myocardial ischemia, or flash pulmonary edema. (See <a href=\"topic.htm?path=acute-opioid-intoxication-in-adults#H13\" class=\"medical medical_review\">&quot;Acute opioid intoxication in adults&quot;, section on 'Management'</a> and <a href=\"topic.htm?path=respiratory-problems-in-the-post-anesthesia-care-unit-pacu#H2646917979\" class=\"medical medical_review\">&quot;Respiratory problems in the post-anesthesia care unit (PACU)&quot;, section on 'Pulmonary edema'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased intracranial pressure if hypercarbia occurs due to hypoventilation. Thus, ventilation is carefully monitored when opioids are administered to a spontaneously breathing patient with a head injury [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/44\" class=\"abstract_t\">44</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bradycardia, which may be severe with high doses of opioids [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/45-47\" class=\"abstract_t\">45-47</a>]. Treatment with a beta-adrenergic agonist (eg, <a href=\"topic.htm?path=ephedrine-systemic-drug-information\" class=\"drug drug_general\">ephedrine</a> 5 to 10 mg) or anticholinergic agent (eg, <a href=\"topic.htm?path=glycopyrrolate-glycopyrronium-drug-information\" class=\"drug drug_general\">glycopyrrolate</a> in 0.2 mg increments up to a total dose of 1 mg, or small incremental doses of <a href=\"topic.htm?path=atropine-drug-information\" class=\"drug drug_general\">atropine</a> 0.2 mg) will typically restore adequate heart rate. (See <a href=\"topic.htm?path=arrhythmias-during-anesthesia#H1803355460\" class=\"medical medical_review\">&quot;Arrhythmias during anesthesia&quot;, section on 'Bradyarrhythmias'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest wall and skeletal muscle rigidity, which may make ventilation difficult. Dose and speed of opioid injection affect the likelihood and severity of rigidity. This problem is most common with <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a>, but can occur with <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> or <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/48-55\" class=\"abstract_t\">48-55</a>].</p><p/><p class=\"bulletIndent1\">Rigidity is prevented or reversed by administration of a neuromuscular blocking agent (NMBA) as soon as the patient is unresponsive and mask ventilation has been successfully established. In spontaneously breathing patients, rigidity can be reversed with <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/48,49\" class=\"abstract_t\">48,49</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Delayed postoperative emergence or delirium. Management of these problems is described separately. (See <a href=\"topic.htm?path=delayed-emergence-and-emergence-delirium-in-adults#H1096447307\" class=\"medical medical_review\">&quot;Delayed emergence and emergence delirium in adults&quot;, section on 'Opioids'</a> and <a href=\"topic.htm?path=delayed-emergence-and-emergence-delirium-in-adults#H1942104686\" class=\"medical medical_review\">&quot;Delayed emergence and emergence delirium in adults&quot;, section on 'Emergence delirium'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Postoperative nausea and vomiting (PONV), particularly with high doses of opioids administered for a prolonged duration [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/56\" class=\"abstract_t\">56</a>]. (See <a href=\"topic.htm?path=postoperative-nausea-and-vomiting#H2162413264\" class=\"medical medical_review\">&quot;Postoperative nausea and vomiting&quot;, section on 'Anesthetic factors'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Postoperative pruritus. This is uncommon if an IV synthetic opioid (eg, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> or <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a>) is administered only during the intraoperative period [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/57\" class=\"abstract_t\">57</a>]. Treatment options include administration of an antihistamine; low doses of an opioid antagonist, such as <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> administered in 4 mcg increments to achieve the desired effect or until the patient experiences an increase in pain; or <a href=\"topic.htm?path=nalbuphine-drug-information\" class=\"drug drug_general\">nalbuphine</a> administered in 1 mg increments to a total of 5 mg [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/58,59\" class=\"abstract_t\">58,59</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Postoperative urinary retention. Management is discussed separately. (See <a href=\"topic.htm?path=overview-of-post-anesthetic-care-for-adult-patients#H154735179\" class=\"medical medical_review\">&quot;Overview of post-anesthetic care for adult patients&quot;, section on 'Inability to void'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Postoperative ileus and constipation. Management is discussed separately. (See <a href=\"topic.htm?path=postoperative-ileus\" class=\"medical medical_review\">&quot;Postoperative ileus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Potential for development of acute tolerance or opioid-induced hyperalgesia (OIH). Acute tolerance is a phenomenon whereby administration of opioids has a diminishing effect over a short period of time [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/60\" class=\"abstract_t\">60</a>]. OIH is characterized by nociceptive sensitization, with greater sensitivity to painful stimuli [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/60-63\" class=\"abstract_t\">60-63</a>]. These phenomena may increase postoperative pain and opioid dose requirements. Though acute tolerance and OIH have been most thoroughly described with prolonged use and higher doses of <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/64-66\" class=\"abstract_t\">64-66</a>], acute tolerance is possible with any opioid. Thus, use of multimodal, opioid-sparing techniques has become the standard of care to limit this issue and other opioid-related adverse effects [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/63\" class=\"abstract_t\">63</a>]. (See <a href=\"topic.htm?path=pain-control-in-the-critically-ill-adult-patient#H196656886\" class=\"medical medical_review\">&quot;Pain control in the critically ill adult patient&quot;, section on 'Multimodal analgesia'</a> and <a href=\"topic.htm?path=pain-control-in-the-critically-ill-adult-patient#H406085831\" class=\"medical medical_review\">&quot;Pain control in the critically ill adult patient&quot;, section on 'Tolerance, withdrawal, and hyperalgesia'</a> and <a href=\"#H4121615153\" class=\"local\">'Chronic opioid use'</a> below and <a href=\"topic.htm?path=prevention-and-management-of-side-effects-in-patients-receiving-opioids-for-chronic-pain#H1335116040\" class=\"medical medical_review\">&quot;Prevention and management of side effects in patients receiving opioids for chronic pain&quot;, section on 'Opioid-induced hyperalgesia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Potential for diversion with abuse, misuse, and opioid-related death if perioperative use leads to postoperative outpatient opioid prescriptions [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/67,68\" class=\"abstract_t\">67,68</a>].</p><p/><p class=\"headingAnchor\" id=\"H153801862\"><span class=\"h1\">DOSING CONSIDERATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Doses of intravenous (IV) opioids are individualized, based on ideal body weight to avoid overdosing, and titrated to the desired analgesic effect in an awake patient, or to supplement other IV and inhalation anesthetics to produce general anesthesia.</p><p>Doses of opioids are reduced in older adult patients and those with impaired renal or hepatic function, and are typically avoided in patients with hemodynamic abnormalities due to hypovolemia, vasodilation, or myocardial dysfunction. (See <a href=\"topic.htm?path=general-anesthesia-intravenous-induction-agents#H4070595924\" class=\"medical medical_review\">&quot;General anesthesia: Intravenous induction agents&quot;, section on 'Dosing considerations'</a>.)</p><p>Higher opioid doses may be necessary to achieve the desired effect in patients who have developed tolerance due to chronic opioid use, compared with those who are opioid naive. (See <a href=\"#H4121615153\" class=\"local\">'Chronic opioid use'</a> below and <a href=\"topic.htm?path=opioid-use-disorder-epidemiology-pharmacology-clinical-manifestations-course-screening-assessment-and-diagnosis#H13085539\" class=\"medical medical_review\">&quot;Opioid use disorder: Epidemiology, pharmacology, clinical manifestations, course, screening, assessment, and diagnosis&quot;, section on 'Tolerance'</a>.)</p><p class=\"headingAnchor\" id=\"H1495146211\"><span class=\"h1\">PERIOPERATIVE USES</span></p><p class=\"headingAnchor\" id=\"H3970381375\"><span class=\"h2\">General anesthesia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intravenous (IV) opioids may be used during the induction, maintenance, or emergence phases of general anesthesia, during monitored anesthesia care (MAC), and to treat pain in the immediate postoperative period. Selection of opioid agents and dosing considerations depend on the specific use, desired speed of onset and offset, procedure-specific factors (eg, degree of analgesia required, planned duration of surgery), patient-specific factors (eg, age, comorbidities, tolerance to opioids), and whether other anesthetics or adjuvant agents are coadministered. (See <a href=\"topic.htm?path=general-anesthesia-intravenous-induction-agents#H240924670\" class=\"medical medical_review\">&quot;General anesthesia: Intravenous induction agents&quot;, section on 'Opioids'</a> and <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence#H861399748\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;, section on 'Opioid agents'</a>.)</p><p class=\"headingAnchor\" id=\"H722402749\"><span class=\"h3\">Preinduction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An opioid (eg, IV <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> 25 to 50 mcg) may be employed as a sole or adjuvant preinduction agent for patients who complain of pain in the immediate preoperative period or for those undergoing a regional anesthetic procedure in the preinduction period. &#160;</p><p class=\"headingAnchor\" id=\"H2978013286\"><span class=\"h3\">Induction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Opioids are the most commonly used adjuvant agents during induction of general anesthesia.</p><p class=\"headingAnchor\" id=\"H1224100467\"><span class=\"h4\">Opioid use as an adjuvant agent</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Typical doses of adjuvant opioid agents used during induction of anesthesia are noted in the table (<a href=\"image.htm?imageKey=ANEST%2F111779\" class=\"graphic graphic_table graphicRef111779 \">table 1</a>). </p><p>During laryngoscopy and endotracheal intubation, administration of an opioid is particularly useful for suppressing airway reflexes that result in coughing <span class=\"nowrap\">and/or</span> bronchospasm [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/18-20\" class=\"abstract_t\">18-20</a>], as well as blunting sympathetic nervous system responses that would otherwise result in tachycardia and hypertension [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/12-17\" class=\"abstract_t\">12-17</a>]. Opioid administration also reduces dose requirements for the selected sedative-hypnotic induction agent [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/5\" class=\"abstract_t\">5</a>]. Furthermore, opioid coadministration with a local anesthetic during induction minimizes pain caused by injection of other agents (eg, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a>, or muscle relaxants) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/21-23,69,70\" class=\"abstract_t\">21-23,69,70</a>].</p><p class=\"headingAnchor\" id=\"H1812591377\"><span class=\"h4\">High-dose opioid induction technique</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In selected patients with poor myocardial function, some clinicians use a high-dose opioid technique for induction of general anesthesia (ie, &ldquo;cardiac induction&rdquo;) if the patient will remain intubated with controlled ventilation for several postoperative hours. Typically, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> 10 to 25 <span class=\"nowrap\">mcg/kg</span> or <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> 1 to 3 <span class=\"nowrap\">mcg/kg</span> is used for this technique. Administration of a large opioid dose to induce anesthesia results in minimal direct myocardial depression and only a small decrease in arterial blood pressure, while minimizing tachycardia <span class=\"nowrap\">and/or</span> hypertension during laryngoscopy and endotracheal intubation. However, a large opioid dose delays extubation, and may cause bradycardia and chest wall rigidity if administered as a bolus. (See <a href=\"topic.htm?path=anesthesia-for-coronary-artery-bypass-grafting-surgery#H1297792077\" class=\"medical medical_review\">&quot;Anesthesia for coronary artery bypass grafting surgery&quot;, section on 'High-dose opioid technique'</a>.) </p><p class=\"headingAnchor\" id=\"H2897922683\"><span class=\"h3\">Maintenance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During the maintenance phase of general anesthesia, an IV opioid is often employed as an adjuvant agent during an inhalation anesthetic technique. Opioids reduce the dose requirement for an inhalation anesthetic (ie, they reduce the minimum alveolar concentration [MAC] of an inhaled agent in the alveoli that is required to prevent movement in response to a surgical stimulus in 50 percent of patients). (See <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence#H302283397\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;, section on 'General considerations'</a>.)</p><p>An opioid is also commonly selected to provide the analgesic component of a total intravenous anesthesia (TIVA) technique, but none is sufficient to produce anesthesia if administered as a sole agent because opioids do not have a hypnotic effect. The addition of an opioid to a TIVA technique allows reduction of the required dose of the selected hypnotic agent, thereby hastening recovery at the end of the procedure. (See <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence#H861399748\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;, section on 'Opioid agents'</a>.)</p><p class=\"headingAnchor\" id=\"H3912015127\"><span class=\"h3\">Emergence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During emergence from general anesthesia, administration of a small dose of IV opioid (eg, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> 25 to 50 mcg) is often employed to attenuate coughing <span class=\"nowrap\">and/or</span> bronchospasm resulting from reflex airway responses to the endotracheal tube or laryngeal mask airway.</p><p class=\"headingAnchor\" id=\"H3696324081\"><span class=\"h2\">Monitored anesthesia care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Opioids are often administered during sedation with monitored anesthesia care (MAC) to provide analgesia during placement of a regional anesthetic block, alleviate discomfort due to uncomfortable positioning, or supplement a regional block during incision and subsequent surgical stimulation. Opioids with rapid onset and short duration of action (eg, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> or <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a>) are generally preferred. Opioid choices and dosing for MAC procedures and patient- and procedure-specific indications are discussed separately. (See <a href=\"topic.htm?path=monitored-anesthesia-care-in-adults#H2441489999\" class=\"medical medical_review\">&quot;Monitored anesthesia care in adults&quot;, section on 'Opioids'</a>.)</p><p class=\"headingAnchor\" id=\"H177868102\"><span class=\"h2\">Treatment of acute postoperative pain</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intravenous opioids are the most widely used therapy to treat postoperative pain because of their ability to provide swift and potent analgesia. Opioid choices, dosing, indications, and cautions in the immediate postoperative period are discussed separately. (See <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H12\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Parenteral opioids'</a>.)</p><p class=\"headingAnchor\" id=\"H3190470157\"><span class=\"h1\">FENTANYL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">Fentanyl</a> is a synthetic derivative of <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a>, in the phenylpiperidine family of opioid agents. It is the most commonly used intraoperative opioid agent for bolus dosing during general anesthesia or monitored anesthesia care (MAC). Fentanyl is 50 to 100 times more potent than morphine. Fentanyl is highly lipophilic, which allows rapid penetration of the blood-brain barrier and rapid onset of action (four to six minutes), although maximal analgesic and respiratory depressant effects of fentanyl may not be evident for several minutes. Fentanyl has the longest duration of action of the agents in the phenylpiperidine family.</p><p class=\"headingAnchor\" id=\"H985440738\"><span class=\"h2\">Uses and dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recommended doses of intravenous (IV) <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> are presented in the table (<a href=\"image.htm?imageKey=ANEST%2F111779\" class=\"graphic graphic_table graphicRef111779 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H1364249633\"><span class=\"h3\">General anesthesia</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Preinduction</strong> &ndash; <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">Fentanyl</a> may be administered in 25 mcg increments in selected patients complaining of pain or requiring a regional anesthetic procedure during the preinduction period; the total preinduction dose is typically &le;100 mcg.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Induction </strong>&ndash; During induction of general anesthesia, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> is often selected as the IV opioid adjuvant agent (see <a href=\"#H2978013286\" class=\"local\">'Induction'</a> above). A typical dose is 25 to 100 mcg (or 0.5 to 1 <span class=\"nowrap\">mcg/kg),</span> administered as a bolus or in divided doses three to five minutes before injection of the sedative-hypnotic induction agent [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=general-anesthesia-intravenous-induction-agents#H240924670\" class=\"medical medical_review\">&quot;General anesthesia: Intravenous induction agents&quot;, section on 'Opioids'</a>.)</p><p/><p class=\"bulletIndent1\">In selected patients with poor myocardial function, a high dose of <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> (eg, 10 to 25 <span class=\"nowrap\">mcg/kg)</span> may be employed to induce general anesthesia if the patient will remain intubated with controlled ventilation for several postoperative hours (eg, after a cardiac surgical procedure). (See <a href=\"topic.htm?path=anesthesia-for-coronary-artery-bypass-grafting-surgery#H1297792077\" class=\"medical medical_review\">&quot;Anesthesia for coronary artery bypass grafting surgery&quot;, section on 'High-dose opioid technique'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Maintenance </strong>&ndash;<strong> </strong>(See <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence#H861399748\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;, section on 'Opioid agents'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Supplemental agent for inhalation technique </strong>&ndash; <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">Fentanyl</a> is often selected to provide supplemental analgesia during maintenance of general anesthesia with an inhalation technique. Typical adult bolus doses are 25 to 50 mcg, administered as needed to provide analgesia and to avoid or treat hemodynamic responses to surgical stimuli (eg, tachycardia, hypertension) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/1\" class=\"abstract_t\">1</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Analgesic component for a TIVA technique</strong> &ndash; <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">Fentanyl</a> may be selected to provide the analgesic component of a total intravenous anesthesia (TIVA) technique, but has a prolonged context-sensitive half time (the time in minutes required for a 50 percent decrease in effect-site concentration after the infusion is discontinued); this leads to delayed recovery (<a href=\"image.htm?imageKey=ANEST%2F109502\" class=\"graphic graphic_figure graphicRef109502 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/1,71,72\" class=\"abstract_t\">1,71,72</a>]. Therefore, fentanyl is not as ideal for TIVA as some other opioid agents (eg, <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a>, <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a>) if extubation is planned at the end of the surgical procedure (see <a href=\"#H4265539633\" class=\"local\">'Remifentanil'</a> below and <a href=\"#H4176363563\" class=\"local\">'Sufentanil'</a> below).</p><p/><p class=\"bulletIndent2\">Occasionally <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> may be selected for infusion during a TIVA technique (eg, when a period of controlled postoperative ventilation is planned). A typical dose is 1 to 2 <span class=\"nowrap\">mcg/kg</span> per hour, with adjustments as needed to deepen analgesia in order to avoid or treat hemodynamic responses to surgical stimuli. Timing discontinuation of the fentanyl infusion is challenging when delayed emergence and respiratory depression are undesirable at the end of the surgical procedure (see <a href=\"#H897171228\" class=\"local\">'Pharmacokinetics'</a> below). </p><p/><p class=\"headingAnchor\" id=\"H3922967017\"><span class=\"h3\">Monitored anesthesia care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">Fentanyl</a> is typically used in small, intermittent IV bolus doses of 25 to 50 mcg during MAC. (See <a href=\"topic.htm?path=monitored-anesthesia-care-in-adults#H2441489999\" class=\"medical medical_review\">&quot;Monitored anesthesia care in adults&quot;, section on 'Opioids'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1394704132\"><span class=\"h3\">Treatment of acute postoperative pain</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">Fentanyl</a> may be administered in the post-anesthesia care unit (PACU) in doses of 25 to 50 mcg every five minutes for moderate acute pain, or in doses of 50 to 100 mcg every two to five minutes for severe acute pain, until the pain is relieved or unwanted adverse effects become evident (eg, respiratory depression, sedation, oxygen saturation &lt;95 percent, hypotension). After initial pain control, the clinician should reassess the postoperative analgesic regimen to determine the best options for further management. (See <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H447934137\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Fentanyl'</a>.) </p><p class=\"headingAnchor\" id=\"H3929588360\"><span class=\"h2\">Advantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the benefits of most opioids (see <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above), <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> has the following specific advantages: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapid onset (three to five minutes).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>High potency (100 times compared with <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Effective analgesia for surgical trauma causing severe pain during the intraoperative or immediate postoperative period, due to a prolonged duration of action.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Minimal effect on myocardial or hemodynamic function.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Absence of histamine-releasing properties; thus, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> is appropriate for patients with bronchospasm.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Generally lower cost compared with <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a>, <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a>, and <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a>. &#160; </p><p/><p class=\"headingAnchor\" id=\"H2463920111\"><span class=\"h2\">Disadvantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the potential adverse effects of most opioids (see <a href=\"#H4025963507\" class=\"local\">'Prevention and management of adverse effects'</a> above), <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> has the following specific disadvantages:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prolonged context-sensitive half time when administered as an infusion (<a href=\"image.htm?imageKey=ANEST%2F109502\" class=\"graphic graphic_figure graphicRef109502 \">figure 1</a>). For example, after infusion of <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> for 200 minutes, approximately 200 more minutes are necessary to achieve a 50 percent decrease in its effect-site concentration. Thus, emergence from general anesthesia may be delayed after a fentanyl infusion. For this reason, we usually avoid a fentanyl infusion for surgical cases of short or intermediate duration.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Brief self-limiting coughing that occasionally occurs after bolus dosing [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/73,74\" class=\"abstract_t\">73,74</a>]. </p><p/><p class=\"headingAnchor\" id=\"H1280607721\"><span class=\"h2\">Drug-drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to synergistic effects with coadministration of <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> and other anesthetic agents (see <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above), possible interactions specific for fentanyl include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serotonergic agents: Coadministration of <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) may increase risk for serotonin syndrome (<a href=\"image.htm?imageKey=EM%2F64604\" class=\"graphic graphic_table graphicRef64604 \">table 2</a>). Management is discussed separately. (See <a href=\"topic.htm?path=serotonin-syndrome-serotonin-toxicity\" class=\"medical medical_review\">&quot;Serotonin syndrome (serotonin toxicity)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CYP3A4 inhibitors: Administration of CYP3A4 inhibitors such as <a href=\"topic.htm?path=diltiazem-drug-information\" class=\"drug drug_general\">diltiazem</a>, <a href=\"topic.htm?path=ritonavir-drug-information\" class=\"drug drug_general\">ritonavir</a>, or <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> may increase plasma levels of <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> since it is metabolized through cytochrome 3A4 [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/75,76\" class=\"abstract_t\">75,76</a>]. Reduction of the fentanyl dose may be necessary when such agents have been administered to avoid adverse opioid effects such as respiratory depression. </p><p/><p class=\"headingAnchor\" id=\"H897171228\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pharmacokinetics for <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> are summarized in the table (<a href=\"image.htm?imageKey=ANEST%2F111780\" class=\"graphic graphic_table graphicRef111780 \">table 3</a>). </p><p><a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">Fentanyl</a> is highly lipophilic, with rapid distribution to highly perfused tissues (eg, brain, heart, kidney, and GI tract). Initial equilibration time is six minutes, with a slower redistribution to muscle and fat [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/77\" class=\"abstract_t\">77</a>].</p><p><a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">Fentanyl</a> has a short duration of action when administered as a bolus dose (30 to 45 minutes) due to its high lipid solubility and redistribution to fatty tissue (<a href=\"image.htm?imageKey=ANEST%2F109504\" class=\"graphic graphic_figure graphicRef109504 \">figure 2</a>). However, fentanyl has a prolonged context-sensitive half time when administered as an infusion, which increases with duration of infusion (<a href=\"image.htm?imageKey=ANEST%2F109502\" class=\"graphic graphic_figure graphicRef109502 \">figure 1</a>). Also, stores in muscle and fat are mobilized after discontinuation of an infusion, potentially contributing to prolonged sedation.</p><p><a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">Fentanyl</a> has a high hepatic extraction ratio of 0.8 to 1.0 such that hepatic blood flow determines the rate of its metabolism. In the liver, fentanyl is metabolized by cytochrome CYP3A4 to norfentanyl, an inactive metabolite that is excreted in the urine. Neither renal nor hepatic insufficiency affects fentanyl pharmacokinetics. The elimination half-life is three to six hours. (See <a href=\"topic.htm?path=anesthesia-for-the-patient-on-dialysis#H127293211\" class=\"medical medical_review\">&quot;Anesthesia for the patient on dialysis&quot;, section on 'Opioids'</a>.)</p><p class=\"headingAnchor\" id=\"H4265539633\"><span class=\"h1\">REMIFENTANIL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil</a> is an ultrashort-acting <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> derivative in the phenylpiperidine family of opioid agents, with a potency that is one to two times that of fentanyl [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/78\" class=\"abstract_t\">78</a>]. Remifentanil is highly lipophilic and has an even more rapid penetration of the blood-brain barrier and more rapid onset of action (one to two minutes) than fentanyl, <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a>, or <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a>. It also has a uniquely short duration of action (5 to 10 minutes after cessation of infusion) because metabolism occurs through esterases located in plasma, red blood cells, and interstitial tissues [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/1,44,79,80\" class=\"abstract_t\">1,44,79,80</a>]. Remifentanil is the most commonly employed agent for infusion during total intravenous anesthesia (TIVA).</p><p class=\"headingAnchor\" id=\"H2617550523\"><span class=\"h2\">Uses and dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recommended doses of <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> are presented in the table (<a href=\"image.htm?imageKey=ANEST%2F111779\" class=\"graphic graphic_table graphicRef111779 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H1979952751\"><span class=\"h3\">General anesthesia</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil</a><strong> intubation technique</strong> &ndash; A remifentanil intubation technique may be employed in selected cases requiring rapid sequence intubation, typically when <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">succinylcholine</a> is contraindicated and the prolonged duration of a nondepolarizing neuromuscular blocking agent (NMBA) is undesirable. (See <a href=\"topic.htm?path=rapid-sequence-induction-and-intubation-rsii-for-anesthesia#H107498333\" class=\"medical medical_review\">&quot;Rapid sequence induction and intubation (RSII) for anesthesia&quot;, section on 'Remifentanil intubation'</a>.)</p><p/><p class=\"bulletIndent1\">For this intubation technique, a high dose of <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> (typically 3 to 5 <span class=\"nowrap\">mcg/kg)</span> is administered as an intravenous (IV) bolus after administration of an induction dose of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>. <a href=\"topic.htm?path=ephedrine-systemic-drug-information\" class=\"drug drug_general\">Ephedrine</a> 10 mg IV is also administered to avoid bradycardia and hypotension that would otherwise result from a high dose of remifentanil combined with propofol (see <a href=\"#H4025963507\" class=\"local\">'Prevention and management of adverse effects'</a> above). This combination of agents provides good intubating conditions within 1 to 2.5 minutes, while blunting the cough reflex and hemodynamic responses (eg, increased heart rate and blood pressure) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/81-83\" class=\"abstract_t\">81-83</a>]. </p><p/><p class=\"bulletIndent1\">A <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> intubation technique is also used by some clinicians for awake fiberoptic intubation [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/19,20\" class=\"abstract_t\">19,20</a>]. Careful titration is employed in a spontaneously breathing patient to relieve pain and suppress airway reflexes, while maintaining the patient&rsquo;s ability to follow commands. However, this use is limited by the respiratory depressant effect of remifentanil. (See <a href=\"topic.htm?path=flexible-scope-intubation-for-anesthesia#H73901562\" class=\"medical medical_review\">&quot;Flexible scope intubation for anesthesia&quot;, section on 'Sedation'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Maintenance</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Analgesic component for a TIVA technique </strong>&ndash; Among the IV opioids, a <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> infusion is the most suitable agent for a total intravenous anesthesia (TIVA) technique, particularly when the intensity of surgical stimulation varies during the procedure. Remifentanil is typically administered in combination with a <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> infusion since both agents have a short-half life and rapid elimination. Thus, recovery is rapid [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/72\" class=\"abstract_t\">72</a>]. For procedures of short to intermediate duration with moderate to intense surgical stimulation, this combination of remifentanil and propofol infusions usually provides satisfactory anesthesia and absence of patient movement. Since the analgesic effect of remifentanil is rapidly terminated after stopping the infusion, its use is most ideal in procedures that incur little or no postoperative pain. (See <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence#H861399748\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;, section on 'Opioid agents'</a>.)</p><p/><p class=\"bulletIndent2\"><a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil</a> is infused at 0.05 to 0.3 <span class=\"nowrap\">mcg/kg</span> per minute beginning during or shortly after induction to maintain anesthesia for a TIVA technique [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/11\" class=\"abstract_t\">11</a>]. We do not usually employ a loading dose since the pharmacokinetics of remifentanil allow attainment of a steady state without loading. Some clinicians do elect to administer a loading dose, typically 0.5 to 1 <span class=\"nowrap\">mcg/kg</span> over 60 to 90 seconds before starting the continuous infusion.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Supplemental agent for inhalation technique </strong>&ndash; <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil</a> may be employed as an adjuvant agent during an inhalation anesthetic technique. Remifentanil infusion at 0.05 to 0.3 <span class=\"nowrap\">mcg/kg</span> per minute improves tolerance to intensely painful surgical stimuli and decreases the required dose of the potent volatile agent [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/2,9\" class=\"abstract_t\">2,9</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil</a><strong> extubation technique</strong> &mdash; In selected cases, it is desirable to avoid all coughing or retching during extubation (eg, when there is patient risk with any increase in intracranial pressure [ICP] or intraocular pressure [IOP]). In such cases, an infusion of remifentanil &ge;0.1 <span class=\"nowrap\">mcg/kg</span> per minute may be briefly administered, with tracheal extubation as soon as the patient can follow commands, which typically occurs before spontaneous respiratory efforts or recovery of airway reflexes. (See <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;</a> and <a href=\"topic.htm?path=anesthesia-for-craniotomy\" class=\"medical medical_review\">&quot;Anesthesia for craniotomy&quot;</a> and <a href=\"topic.htm?path=anesthesia-for-emergent-eye-surgery\" class=\"medical medical_review\">&quot;Anesthesia for emergent eye surgery&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H4261605709\"><span class=\"h3\">Monitored anesthesia care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil</a> may be administered as an infusion during monitored anesthesia care (MAC), with or without initial or intermittent bolus doses. Details regarding this use are discussed separately. (See <a href=\"topic.htm?path=monitored-anesthesia-care-in-adults#H2441489999\" class=\"medical medical_review\">&quot;Monitored anesthesia care in adults&quot;, section on 'Opioids'</a>.)</p><p class=\"headingAnchor\" id=\"H1558056750\"><span class=\"h2\">Advantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the benefits of most opioids (see <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above), <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> has the following specific advantages:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fastest onset of action compared with all other opioids (one to two minutes).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapid attainment of steady state after a bolus dose (<a href=\"image.htm?imageKey=ANEST%2F109503\" class=\"graphic graphic_figure graphicRef109503 \">figure 3</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapid offset due to a very short context-sensitive half time after administration as an infusion (approximately five minutes), regardless of the duration of infusion (<a href=\"image.htm?imageKey=ANEST%2F109502\" class=\"graphic graphic_figure graphicRef109502 \">figure 1</a>). This allows rapid titration to change anesthetic depth during maintenance, as well as a quick recovery during emergence. (See <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence#H3871707239\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;, section on 'Preparations for emergence'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ideal when early recovery and assessment of neurologic function are necessary, due to its rapid elimination [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/84\" class=\"abstract_t\">84</a>]. (See <a href=\"topic.htm?path=anesthesia-for-craniotomy#H356126656\" class=\"medical medical_review\">&quot;Anesthesia for craniotomy&quot;, section on 'Our anesthesia strategy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unaffected by hepatic or renal insufficiency because it is metabolized by ester hydrolysis in the blood and tissues.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Possible lower incidence of postoperative nausea and vomiting (PONV), allowing more rapid discharge from the post-anesthesia care unit (PACU), compared with <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/85\" class=\"abstract_t\">85</a>].</p><p/><p class=\"headingAnchor\" id=\"H125978762\"><span class=\"h2\">Disadvantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the potential adverse effects of most opioids (see <a href=\"#H4025963507\" class=\"local\">'Prevention and management of adverse effects'</a> above), <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> has the following specific disadvantages:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Generally higher cost than other opioids, particularly if used for long surgical cases. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Likelihood of muscle and chest wall rigidity with rapid administration of high doses. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Higher incidence of hypotension compared with other opioids [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/86\" class=\"abstract_t\">86</a>]. In some cases, this may be due to the greater potency of <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> compared with <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> since remifentanil is often used as if it is equipotent [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/78\" class=\"abstract_t\">78</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Possible tachyphylaxis during administration [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/64\" class=\"abstract_t\">64</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Need for administration of an alternative analgesic agent or technique during emergence <span class=\"nowrap\">and/or</span> the immediate postoperative period if postoperative pain is anticipated, because the analgesic effect of <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> is terminated within minutes of discontinuing its infusion [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/80\" class=\"abstract_t\">80</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Possible acute tolerance and opioid-induced hyperalgesia (OIH) after discontinuation of a <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> infusion [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/87,88\" class=\"abstract_t\">87,88</a>]. These adverse effects are dose-dependent and more likely with high doses &gt;0.3 <span class=\"nowrap\">mcg/kg</span> per minute or a cumulative dose &gt;50 <span class=\"nowrap\">mcg/kg</span> [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/64-66\" class=\"abstract_t\">64-66</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Higher incidence of postoperative shivering compared with other opioids [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/89\" class=\"abstract_t\">89</a>].</p><p/><p class=\"headingAnchor\" id=\"H1011953393\"><span class=\"h2\">Drug-drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Except for the synergistic effects with coadministration of other anesthetic agents (see <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above), <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> has minimal drug interactions due to its rapid metabolism.</p><p class=\"headingAnchor\" id=\"H906498990\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pharmacokinetics for <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> are summarized in the table (<a href=\"image.htm?imageKey=ANEST%2F111780\" class=\"graphic graphic_table graphicRef111780 \">table 3</a>).</p><p><a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil</a> is highly lipophilic, with extremely rapid distribution to highly perfused tissues (eg, brain, heart, kidney, and gastrointestinal tract). Initial equilibration time is one to two minutes.</p><p><a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil</a> has a very short duration of action, with a context-sensitive half time of four minutes (<a href=\"image.htm?imageKey=ANEST%2F109502\" class=\"graphic graphic_figure graphicRef109502 \">figure 1</a>). It is metabolized by nonspecific plasma esterases in the plasma, red blood cells, and interstitial tissue to an inactive metabolite (remifentanil acid), which is subsequently excreted unchanged in the urine. Elimination half-life for remifentanil is 10 to 20 minutes [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/44,80,90\" class=\"abstract_t\">44,80,90</a>]. There is no evidence of accumulation in patients with renal <span class=\"nowrap\">and/or</span> hepatic dysfunction.</p><p class=\"headingAnchor\" id=\"H4176363563\"><span class=\"h1\">SUFENTANIL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">Sufentanil</a> is a phenylpiperidine opioid that is approximately 10 times more potent than <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> and is used in similar settings [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/1,71,91\" class=\"abstract_t\">1,71,91</a>]. Like fentanyl, sufentanil is highly lipophilic with rapid onset (three to five minutes) and low cost compared with newer synthetic opioids such as <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a>.</p><p class=\"headingAnchor\" id=\"H2867551102\"><span class=\"h2\">Uses and dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recommended doses of <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> are presented in the table (<a href=\"image.htm?imageKey=ANEST%2F111779\" class=\"graphic graphic_table graphicRef111779 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/92\" class=\"abstract_t\">92</a>].</p><p class=\"headingAnchor\" id=\"H3166497392\"><span class=\"h3\">General anesthesia</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Induction</strong> &ndash; During induction of general anesthesia, <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> is often selected as the intravenous (IV) opioid adjuvant agent (see <a href=\"#H2978013286\" class=\"local\">'Induction'</a> above). A typical dose is 0.1 to 0.2 <span class=\"nowrap\">mcg/kg,</span> administered in divided doses three to five minutes prior to the sedative-hypnotic induction agent. (See <a href=\"topic.htm?path=general-anesthesia-intravenous-induction-agents#H240924670\" class=\"medical medical_review\">&quot;General anesthesia: Intravenous induction agents&quot;, section on 'Opioids'</a>.)</p><p/><p class=\"bulletIndent1\">In selected patients with poor myocardial function, a high dose of <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> (eg, 1 to 3 <span class=\"nowrap\">mcg/kg)</span> may be employed to induce general anesthesia if the patient will remain intubated with controlled ventilation for several postoperative hours (eg, after a cardiac surgical procedure). (See <a href=\"topic.htm?path=anesthesia-for-coronary-artery-bypass-grafting-surgery#H1297792077\" class=\"medical medical_review\">&quot;Anesthesia for coronary artery bypass grafting surgery&quot;, section on 'High-dose opioid technique'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Maintenance</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Supplemental agent for inhalation technique</strong> &ndash; During maintenance of general anesthesia with an inhalation technique, <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> is often the selected adjuvant opioid agent. Typically, 5 to 10 mcg bolus doses are administered as necessary to provide supplemental analgesia or to treat hemodynamic responses to surgical stimulation (eg, tachycardia, hypertension) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Analgesic component for a TIVA technique </strong>&ndash; <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">Sufentanil</a> may be selected to provide the analgesic component of general anesthesia with a total intravenous anesthesia (TIVA) technique, particularly in cases with a prolonged duration (eg, cardiac and neurologic surgery) when rapid emergence is not needed. Typically, 5 to 10 mcg bolus doses or a continuous infusion at 0.5 to 1.5 <span class=\"nowrap\">mcg/kg</span> per hour (or 0.008 to 0.025 <span class=\"nowrap\">mcg/kg</span> per minute) is administered. Although sufentanil has a shorter context-sensitive half time than <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a>, it is longer than that of <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> (<a href=\"image.htm?imageKey=ANEST%2F109502\" class=\"graphic graphic_figure graphicRef109502 \">figure 1</a>), with a slower return of neurocognitive function. However, unlike remifentanil, sufentanil has the advantage of providing an analgesic effect into the postoperative period. (See <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence#H861399748\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;, section on 'Opioid agents'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H4127321796\"><span class=\"h2\">Advantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the benefits of most opioids (see <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above), <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> has the following specific advantages:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapid onset (three to five minutes for peak effect).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>High potency (5 to 10 times more potent than <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Shorter context-sensitive half time compared with <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> (<a href=\"image.htm?imageKey=ANEST%2F109502\" class=\"graphic graphic_figure graphicRef109502 \">figure 1</a>). Thus, recovery is more rapid after infusions lasting several hours, compared with equipotent doses of fentanyl [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/93\" class=\"abstract_t\">93</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low cost compared with <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ideal for longer procedures when continuous opioid administration and a postoperative analgesic effect are desirable.</p><p/><p class=\"headingAnchor\" id=\"H1241061197\"><span class=\"h2\">Disadvantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the potential adverse effects of most opioids (see <a href=\"#H4025963507\" class=\"local\">'Prevention and management of adverse effects'</a> above), a specific disadvantage for <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> is the likelihood of muscle and chest wall rigidity, particularly if sufentanil is rapidly injected or if high doses are administered [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/49-51\" class=\"abstract_t\">49-51</a>].</p><p class=\"headingAnchor\" id=\"H3219764222\"><span class=\"h2\">Drug-drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Synergistic effects occur with coadministration of <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> and other anesthetic agents (see <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above).</p><p class=\"headingAnchor\" id=\"H3794233678\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pharmacokinetics for <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> are summarized in the table (<a href=\"image.htm?imageKey=ANEST%2F111780\" class=\"graphic graphic_table graphicRef111780 \">table 3</a>).</p><p><a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">Sufentanil</a> is rapidly distributed to highly perfused tissues with an initial equilibration time of six minutes. The context-sensitive half time is shorter than that for <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a>, but longer than for <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> (<a href=\"image.htm?imageKey=ANEST%2F109502\" class=\"graphic graphic_figure graphicRef109502 \">figure 1</a>). For example, after continuous infusion of sufentanil for 200 minutes, a 50 percent decrease in its effect-site concentration occurs in 30 to 45 minutes, compared with approximately 200 minutes for fentanyl or four minutes for remifentanil.</p><p><a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">Sufentanil</a> is metabolized in both the small intestine and liver, and is excreted in the urine. Its elimination half-life is two to four hours [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/44,92,94\" class=\"abstract_t\">44,92,94</a>].</p><p class=\"headingAnchor\" id=\"H4207798916\"><span class=\"h1\">ALFENTANIL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">Alfentanil</a> is a phenylpiperidine opioid that is approximately three times less potent than <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> and is used in similar settings [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/1,71,91\" class=\"abstract_t\">1,71,91</a>]. It is highly lipophilic, allowing very rapid penetration of the blood-brain barrier and rapid onset of action (one to three minutes). The cost for alfentanil is intermediate between that of&nbsp;<a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a> and <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a>.</p><p class=\"headingAnchor\" id=\"H1206610327\"><span class=\"h2\">Uses and dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recommended doses of <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a> are presented in the table (<a href=\"image.htm?imageKey=ANEST%2F111779\" class=\"graphic graphic_table graphicRef111779 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H575561191\"><span class=\"h3\">General anesthesia</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Induction</strong> &ndash; During induction of general anesthesia, <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a> is occasionally selected as the intravenous (IV) opioid adjuvant agent (see <a href=\"#H2978013286\" class=\"local\">'Induction'</a> above). A typical adult dose is 50 to 100 <span class=\"nowrap\">mcg/kg,</span> or smaller doses of 500 mcg, which may be repeated until the desired effect is achieved.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Maintenance</strong> &ndash; During maintenance of general anesthesia with an inhalation technique, <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a> is occasionally selected to provide supplemental analgesia. Typically, small IV doses of 500 mcg are titrated as necessary to provide analgesia and to avoid or treat hemodynamic responses to surgical stimuli (eg, tachycardia, hypertension) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/1\" class=\"abstract_t\">1</a>]. Alfentanil has a context-sensitive half time similar to that for <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> (<a href=\"image.htm?imageKey=ANEST%2F109502\" class=\"graphic graphic_figure graphicRef109502 \">figure 1</a>), and is suitable for cases lasting longer than six hours when a rapid decrease in opioid effect is desirable [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/95\" class=\"abstract_t\">95</a>]. The dose range for continuous infusion of alfentanil is 0.5 to 1.5 <span class=\"nowrap\">mcg/kg</span> per minute. (See <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence#H861399748\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;, section on 'Opioid agents'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1196586843\"><span class=\"h2\">Advantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the benefits of most opioids (see <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above), <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a> has the following specific advantages:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Very rapid onset of action (one to three minutes) which is faster than <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> but slightly less rapid than <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a>. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapid attainment of steady state after a bolus dose.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Shorter context-sensitive half time compared with <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> (similar to that for <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a>) (<a href=\"image.htm?imageKey=ANEST%2F109502\" class=\"graphic graphic_figure graphicRef109502 \">figure 1</a>).</p><p/><p class=\"headingAnchor\" id=\"H4263926894\"><span class=\"h2\">Disadvantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the potential adverse effects of most opioids (see <a href=\"#H4025963507\" class=\"local\">'Prevention and management of adverse effects'</a> above), a major disadvantage for <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a> is focal activation of the cerebral cortex in susceptible patients, which produces seizure-like electrical activity that can be identified with electroencephalogram (EEG) monitoring. Thus, alfentanil is avoided in patients with risk factors for seizures.</p><p class=\"headingAnchor\" id=\"H2682376348\"><span class=\"h2\">Drug-drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Synergistic effects occur with coadministration of <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a> and other anesthetic agents (see <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above). Similar to <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a>, interactions with CYP3A4 inhibitors such as <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> may increase plasma levels of alfentanil since it is metabolized through cytochrome 3A4 [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/96\" class=\"abstract_t\">96</a>].</p><p class=\"headingAnchor\" id=\"H1538695758\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pharmacokinetics for <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a> are summarized in the table (<a href=\"image.htm?imageKey=ANEST%2F111780\" class=\"graphic graphic_table graphicRef111780 \">table 3</a>).</p><p><a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">Alfentanil</a> is rapidly distributed to highly perfused tissues with an initial equilibration time of one to three minutes [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/95\" class=\"abstract_t\">95</a>]. Its context-sensitive half time is comparable to that of <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> (ie, 30 to 45 minutes).</p><p>Hepatic metabolism of <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a> is less predictable than for <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> and <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a> due to significant inter-individual variability in activity of hepatic CYP3A4 (the enzyme primarily responsible for biotransformation of alfentanil). Elimination half-life is typically 1.5 to 2 hours.</p><p class=\"headingAnchor\" id=\"H2455208050\"><span class=\"h1\">HYDROMORPHONE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">Hydromorphone</a> is a phenanthrene opioid that is a semi-synthetic <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> derivative. Compared with morphine, hydromorphone is approximately five times more potent, has a slightly more rapid onset (with a peak effect within 10 minutes after intravenous [IV] administration [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/97\" class=\"abstract_t\">97</a>]), and a shorter half-life of 2.4 hours [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/98\" class=\"abstract_t\">98</a>].</p><p class=\"headingAnchor\" id=\"H3630954278\"><span class=\"h2\">Uses and dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recommended doses of <a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">hydromorphone</a> are presented in the table (<a href=\"image.htm?imageKey=ANEST%2F111779\" class=\"graphic graphic_table graphicRef111779 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H189190759\"><span class=\"h3\">General anesthesia</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Maintenance</strong> &ndash; <a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">Hydromorphone</a> may be the selected opioid to provide supplemental analgesia with either an inhalation anesthetic or a total intravenous anesthesia (TIVA) technique. Typically, small IV bolus doses of hydromorphone 0.25 to 0.5 mg are administered as necessary. (See <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence#H861399748\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;, section on 'Opioid agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Emergence</strong> &ndash; Similar to <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a>, small boluses of <a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">hydromorphone</a> may be administered near the end of surgery to control postoperative pain, typically to a total dose of 0.25 to 1 mg (see <a href=\"#H1589351287\" class=\"local\">'Uses and dosing'</a> below).</p><p/><p class=\"headingAnchor\" id=\"H2677374416\"><span class=\"h3\">Treatment of acute postoperative pain</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For postoperative analgesia, we typically administer a long-acting opioid such as IV <a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">hydromorphone</a> 0.01 <span class=\"nowrap\">mg/kg</span> approximately 20 to 30 minutes before anticipated tracheal extubation. In the post-anesthesia care unit (PACU), dosing for acute pain is 0.2 to 0.5 mg IV every five minutes until pain is relieved or unwanted adverse effects become evident (eg, respiratory depression, sedation, oxygen saturation &lt;95 percent, hypotension). After initial pain control, 0.2 to 0.5 mg IV every three to four hours is typically needed. (See <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H447934131\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Hydromorphone'</a>.) </p><p class=\"headingAnchor\" id=\"H2870541\"><span class=\"h2\">Advantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the benefits of most opioids (see <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above), <a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">hydromorphone</a> has the following specific advantages:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low cost and wide availability.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prolonged duration of action (four to six hours), similar to <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a>. This is an advantage if severe postoperative pain is anticipated.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Analgesic efficacy that is slightly better than <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/98\" class=\"abstract_t\">98</a>].</p><p/><p class=\"headingAnchor\" id=\"H453525651\"><span class=\"h2\">Disadvantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the potential adverse effects of most opioids (see <a href=\"#H4025963507\" class=\"local\">'Prevention and management of adverse effects'</a> above), <a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">hydromorphone</a> has the following specific disadvantages:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Slower onset of analgesia (5 to 10 minutes) and slower time to peak analgesic effect compared with the synthetic agents (eg, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a>, <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a>, <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a>, <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a>), due to lower lipid solubility and a longer lag time for penetration of the blood-brain barrier.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Long context-sensitive half time (approximately two to three hours) (<a href=\"image.htm?imageKey=ANEST%2F109502\" class=\"graphic graphic_figure graphicRef109502 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/99,100\" class=\"abstract_t\">99,100</a>]. <a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">Hydromorphone</a> is not typically used as a continuous infusion since it is difficult to titrate when rapid changes in anesthetic depth are necessary.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Caution with use in patients with renal insufficiency (creatinine clearance less than 30 <span class=\"nowrap\">mL/minute)</span> due to likely accumulation of its renally-excreted potentially neurotoxic hydromorphone-3-glucuronide metabolite. (See <a href=\"topic.htm?path=anesthesia-for-the-patient-on-dialysis#H127293211\" class=\"medical medical_review\">&quot;Anesthesia for the patient on dialysis&quot;, section on 'Opioids'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cautious use in patients with seizures due to neuroexcitation caused by its hydromorphone-3-glucuronide metabolite, with possible occurrence of myoclonus or exacerbation of seizure activity. </p><p/><p class=\"headingAnchor\" id=\"H908188094\"><span class=\"h2\">Drug-drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Synergistic effects occur with coadministration of <a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">hydromorphone</a> and other anesthetic agents (see <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above).</p><p class=\"headingAnchor\" id=\"H2151248242\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pharmacokinetics for <a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">hydromorphone</a> are summarized in the table (<a href=\"image.htm?imageKey=ANEST%2F111780\" class=\"graphic graphic_table graphicRef111780 \">table 3</a>).</p><p><a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">Hydromorphone</a> is primarily metabolized in the liver; thus, dose is reduced in patients with hepatic insufficiency. Its hydromorphone-3-glucuronide metabolite is renally excreted. Although this metabolite is effectively removed during hemodialysis, it may accumulate and cause neuroexcitation between dialysis treatments (see <a href=\"#H453525651\" class=\"local\">'Disadvantages'</a> above) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/101\" class=\"abstract_t\">101</a>].</p><p class=\"headingAnchor\" id=\"H3027426084\"><span class=\"h1\">MORPHINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">Morphine</a> is the prototype opioid agent. It is a phenanthrene opioid that is less lipophilic than the synthetic opioids (eg, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a>, <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a>, <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a>, <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a>), which results in slower onset of action compared with other opioids (within 20 minutes) due to poor penetration of the blood-brain barrier [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/102\" class=\"abstract_t\">102</a>]. However, morphine has a long analgesic duration of four to five hours. For this reason, it is often selected to preemptively <span class=\"nowrap\">and/or</span> urgently control postoperative pain.</p><p class=\"headingAnchor\" id=\"H1589351287\"><span class=\"h2\">Uses and dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recommended doses of intravenous (IV) <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> are presented in the table (<a href=\"image.htm?imageKey=ANEST%2F111779\" class=\"graphic graphic_table graphicRef111779 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H111566137\"><span class=\"h3\">General anesthesia</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Maintenance </strong>&ndash; Bolus dosing of <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> during the maintenance phase of anesthesia is less common since the development of shorter-acting intravenous (IV) opioids (eg, <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a>, <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a>, <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a>). If selected, small IV bolus doses of morphine 1 to 2 mg are titrated as necessary [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/103\" class=\"abstract_t\">103</a>]. (See <a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence#H861399748\" class=\"medical medical_review\">&quot;General anesthesia: Maintenance and emergence&quot;, section on 'Opioid agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Emergence</strong> &ndash; Bolus dosing of <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> near the end of surgery to a total of 1 to 5 mg is often employed to preemptively control postoperative pain, with reduced doses for patients &gt;65 years old and those with hepatic insufficiency [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/104,105\" class=\"abstract_t\">104,105</a>].</p><p/><p class=\"headingAnchor\" id=\"H2163730101\"><span class=\"h3\">Treatment of acute postoperative pain</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For postoperative analgesia, we typically administer a long-acting opioid such as IV <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> 0.1 <span class=\"nowrap\">mg/kg</span> approximately 20 to 30 minutes before anticipated tracheal extubation. In the post-anesthesia care unit (PACU), dosing for acute pain is 1 to 3 mg every five minutes until pain is relieved or unwanted adverse effects become evident (eg, respiratory depression, sedation, oxygen saturation &lt;95 percent, hypotension) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/106\" class=\"abstract_t\">106</a>]. After initial pain control, 1 to 3 mg IV every three to four hours is typically needed. (See <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H447934122\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Morphine'</a>.) &#160;</p><p class=\"headingAnchor\" id=\"H1272516313\"><span class=\"h2\">Advantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the benefits of most opioids (see <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above), <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> has the following specific advantages:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low cost and wide availability.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prolonged duration of action (four to six hours). This is an advantage if severe postoperative pain is anticipated.</p><p/><p class=\"headingAnchor\" id=\"H219866222\"><span class=\"h2\">Disadvantages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the potential adverse effects of most opioids (see <a href=\"#H4025963507\" class=\"local\">'Prevention and management of adverse effects'</a> above), <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> has the following specific disadvantages:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Slower onset of analgesia (within 20 minutes) and slower time to peak analgesic effect compared with the synthetic opioids (eg, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a>, <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">remifentanil</a>, <a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">sufentanil</a>, <a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">alfentanil</a>), due to lower lipid solubility and a longer lag time for penetration of the blood-brain barrier.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Long context-sensitive half time (approximately 4.5 hours) (<a href=\"image.htm?imageKey=ANEST%2F109502\" class=\"graphic graphic_figure graphicRef109502 \">figure 1</a>). Use of <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> as a continuous infusion is generally avoided since it is difficult to titrate when rapid changes in anesthetic depth are necessary.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Higher incidence of most opioid-related adverse side effects (eg, pruritus, urinary retention, constipation, and nausea), compared with other opioids.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Association with histamine release that may result in facial flushing, pruritus, diaphoresis, and hypotension.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased tone or spasm of the sphincter of Oddi and the common bile duct, which diminishes biliary and pancreatic secretions and may lead to biliary colic.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unsuitable for patients with hemodynamic instability due to possible exacerbation of hypotension by histamine release, as well as persistence of its effects due to a long context-sensitive half time and the mu-receptor-stimulating properties of its morphine-6-glucuronide metabolite (see <a href=\"#H3279440888\" class=\"local\">'Pharmacokinetics'</a> below).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unsuitable for patients with renal insufficiency (creatinine clearance less than 30 <span class=\"nowrap\">mL/minute)</span> due to likely accumulation of its renally-excreted, potentially neurotoxic morphine-6-glucuronide metabolite. This metabolite also has mu-receptor-stimulating properties which may prolong the effects of <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/107,108\" class=\"abstract_t\">107,108</a>]. (See <a href=\"topic.htm?path=anesthesia-for-the-patient-on-dialysis#H127293211\" class=\"medical medical_review\">&quot;Anesthesia for the patient on dialysis&quot;, section on 'Opioids'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cautious use in patients with a history of seizures due to neuroexcitation caused by the morphine-6-glucuronide metabolite, with possible occurrence of myoclonus or exacerbation of seizure activity. &#160;</p><p/><p class=\"headingAnchor\" id=\"H2396470625\"><span class=\"h2\">Drug-drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">Morphine</a> has synergistic effects with coadministration of other anesthetic agents (see <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above).</p><p class=\"headingAnchor\" id=\"H3279440888\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pharmacokinetics for <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> are summarized in the table (<a href=\"image.htm?imageKey=ANEST%2F111780\" class=\"graphic graphic_table graphicRef111780 \">table 3</a>).</p><p>Onset of action after administration of an IV dose of <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> is within 10 minutes, with a peak effect after 15 to 30 minutes [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/106\" class=\"abstract_t\">106</a>]. Morphine is primarily metabolized in the liver to glucuronide metabolites, morphine-6-glucuronide and morphine-3-glucuronide; thus, dose is reduced for patients with hepatic insufficiency. Morphine-6-glucuronide produces ongoing analgesia due to mu-receptor-stimulating properties [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/108\" class=\"abstract_t\">108</a>].</p><p>The elimination half-life for <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> is two to three hours, but up to seven hours are required for the elimination half-life of its morphine-6-glucuronide metabolite [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/95\" class=\"abstract_t\">95</a>]. Renal elimination is typically complete within 24 hours.</p><p class=\"headingAnchor\" id=\"H3721078605\"><span class=\"h1\">CHRONIC OR ACUTE OPIOID USE/ABUSE</span></p><p class=\"headingAnchor\" id=\"H4121615153\"><span class=\"h2\">Chronic opioid use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients who use opioids chronically may develop tolerance, withdrawal symptoms, <span class=\"nowrap\">and/or</span> opioid-induced hyperalgesia, which may necessitate use of higher opioid doses or alternative agents or techniques to provide analgesia in the perioperative period. (See <a href=\"topic.htm?path=pain-control-in-the-critically-ill-adult-patient#H406085831\" class=\"medical medical_review\">&quot;Pain control in the critically ill adult patient&quot;, section on 'Tolerance, withdrawal, and hyperalgesia'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Tolerance </strong>&ndash; Patients who have received prolonged or high daily opioid doses typically develop tolerance, a phenomenon whereby administration of opioids has a diminishing effect over time. This can usually be overcome with higher doses of opioids, although the risk of opioid-related adverse effects is increased with this strategy [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/109-111\" class=\"abstract_t\">109-111</a>]. Thus, perioperative use of multimodal, opioid-sparing techniques have become the standard of care. Options include use of continuous neuraxial or peripheral regional analgesia techniques, nonopioid analgesics such as <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">acetaminophen</a>, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase (COX)-2 specific inhibitors, <span class=\"nowrap\">and/or</span> adjuvant inhalation or intravenous agents with analgesic properties (eg, <a href=\"topic.htm?path=nitrous-oxide-drug-information\" class=\"drug drug_general\">nitrous oxide</a>, <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a>, <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a>, gabapentinoids). (See <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H447933291\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Strategy for perioperative pain control'</a>.)</p><p/><p class=\"bulletIndent1\">For tolerant patients who are chronically receiving <a href=\"topic.htm?path=methadone-drug-information\" class=\"drug drug_general\">methadone</a> or <a href=\"topic.htm?path=buprenorphine-drug-information\" class=\"drug drug_general\">buprenorphine</a>, management of acute pain is discussed separately [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/109-111\" class=\"abstract_t\">109-111</a>]. (See <a href=\"topic.htm?path=management-of-acute-pain-in-the-patient-chronically-using-opioids#H2978047\" class=\"medical medical_review\">&quot;Management of acute pain in the patient chronically using opioids&quot;, section on 'Methadone maintenance therapy'</a> and <a href=\"topic.htm?path=management-of-acute-pain-in-the-patient-chronically-using-opioids#H2978054\" class=\"medical medical_review\">&quot;Management of acute pain in the patient chronically using opioids&quot;, section on 'Buprenorphine'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Withdrawal symptoms </strong>&ndash; Acute opioid withdrawal may occur when opioids are abruptly discontinued, particularly if high daily doses have been administered over a prolonged period. Classic symptoms due to rebound increases in neurotransmitter release may be exacerbated by inadequate relief of surgical pain. These include sweating, lacrimation, tachycardia, and hypertension (as well as anxiety, nausea, and vomiting in an awake patient) (<a href=\"image.htm?imageKey=EM%2F81045\" class=\"graphic graphic_table graphicRef81045 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/109,112\" class=\"abstract_t\">109,112</a>]. (See <a href=\"topic.htm?path=opioid-withdrawal-in-the-emergency-setting#H4\" class=\"medical medical_review\">&quot;Opioid withdrawal in the emergency setting&quot;, section on 'Clinical features of opioid withdrawal'</a>.)</p><p/><p class=\"bulletIndent1\">Opioid withdrawal symptoms are assessed with validated scale such as the Clinical Opiate Withdrawal Scale (COWS) in the perioperative period (<a href=\"image.htm?imageKey=PSYCH%2F106994\" class=\"graphic graphic_table graphicRef106994 \">table 5</a>) [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/113,114\" class=\"abstract_t\">113,114</a>]. As with opioid-tolerant patients, multi-modal analgesia techniques are used whenever feasible to maximize analgesia and minimize opioid-related adverse effects. In addition, an alpha<sub>2</sub> agonist, typically <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a>, may be administered to reduce the undesirable physiologic effects of opioid withdrawal [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/109,115,116\" class=\"abstract_t\">109,115,116</a>]. (See <a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal#H19\" class=\"medical medical_review\">&quot;Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal&quot;, section on 'Withdrawal'</a> and <a href=\"topic.htm?path=opioid-withdrawal-in-the-emergency-setting#H9\" class=\"medical medical_review\">&quot;Opioid withdrawal in the emergency setting&quot;, section on 'Management'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Opioid-induced hyperalgesia </strong>&ndash; Opioid-induced hyperalgesia (OIH) is a condition that may develop in patients chronically exposed to opioids. OIH is caused by nociceptive sensitization and is characterized by greater than expected sensitivity to painful stimuli <span class=\"nowrap\">and/or</span> a paradoxical hyperalgesic response when an opioid is administered [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/61,63\" class=\"abstract_t\">61,63</a>]. Thus, nonopioid techniques and agents are employed to provide adequate perioperative analgesia when possible, similar to management of opioid tolerance. (See <a href=\"topic.htm?path=prevention-and-management-of-side-effects-in-patients-receiving-opioids-for-chronic-pain#H1335116040\" class=\"medical medical_review\">&quot;Prevention and management of side effects in patients receiving opioids for chronic pain&quot;, section on 'Opioid-induced hyperalgesia'</a>.) </p><p/><p class=\"headingAnchor\" id=\"H2933998852\"><span class=\"h2\">Acute opioid intoxication</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with acute opioid intoxication may require emergency surgery (eg, after trauma). These patients have increased risk for opioid adverse effects. For example, acutely intoxicated patients may develop respiratory depression if the opioid of abuse has not been eliminated from the patient's system, particularly if additional opioids are administered during the perioperative period. Thus, it is helpful to determine the opioid agent, likely dose, and time of most recent administration to estimate duration of effect.</p><p>Conversely, patients who have used opioids chronically may have developed tolerance, as noted above; thus, control of postoperative pain may be challenging [<a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/109,110\" class=\"abstract_t\">109,110</a>]. For these reasons, perioperative analgesic management with nonopioid techniques and agents is employed when possible, similar to patients receiving chronic opioid therapy (see <a href=\"#H4121615153\" class=\"local\">'Chronic opioid use'</a> above).</p><p class=\"headingAnchor\" id=\"H2730096515\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Benefits of perioperative use of intravenous (IV) opioids include effective analgesia, reduced requirements for other IV and inhalation anesthetic agents, attenuation of autonomic responses to noxious stimuli, and blunting of cough and gag reflexes during airway manipulation. (See <a href=\"#H2754072954\" class=\"local\">'Benefits'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Potential adverse effects of opioids include exacerbation of hypotensive effects of other anesthetic agents (eg, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, inhalation anesthetics), respiratory depression <span class=\"nowrap\">and/or</span> apnea, increased intracranial pressure (if hypoventilation results in hypercarbia), bradycardia, chest wall and skeletal muscle rigidity, postoperative delayed emergence, nausea and vomiting, pruritus, urinary retention, and potential for acute tolerance and opioid-induced hyperalgesia. (See <a href=\"#H4025963507\" class=\"local\">'Prevention and management of adverse effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Doses of opioids are based on ideal body weight and are titrated to the desired analgesic effect. Doses are reduced with coadministration of anesthetic agents from other pharmacologic classes, older age or impaired renal or hepatic function, or hemodynamic abnormalities due to hypovolemia, vasodilation, or myocardial dysfunction. (See <a href=\"#H153801862\" class=\"local\">'Dosing considerations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>IV opioids may be employed for several specific purposes during the perioperative period (see <a href=\"#H1495146211\" class=\"local\">'Perioperative uses'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Provision of analgesia during the preinduction, induction, maintenance, <span class=\"nowrap\">and/or</span> emergence phases of general anesthesia. (See <a href=\"#H3970381375\" class=\"local\">'General anesthesia'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Provision of analgesia and supplemental sedation during monitored anesthesia care (MAC). (See <a href=\"#H3696324081\" class=\"local\">'Monitored anesthesia care'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Treatment of postoperative pain. (See <a href=\"#H177868102\" class=\"local\">'Treatment of acute postoperative pain'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Specific uses, dosing, advantages, disadvantages, drug-drug interactions, and pharmacokinetics for opioids used during the perioperative period differ for each agent:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">Fentanyl</a> (see <a href=\"#H3190470157\" class=\"local\">'Fentanyl'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil</a> (see <a href=\"#H4265539633\" class=\"local\">'Remifentanil'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=sufentanil-drug-information\" class=\"drug drug_general\">Sufentanil</a> (see <a href=\"#H4176363563\" class=\"local\">'Sufentanil'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=alfentanil-drug-information\" class=\"drug drug_general\">Alfentanil</a> (see <a href=\"#H4207798916\" class=\"local\">'Alfentanil'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">Hydromorphone</a> (see <a href=\"#H2455208050\" class=\"local\">'Hydromorphone'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">Morphine</a> (see <a href=\"#H3027426084\" class=\"local\">'Morphine'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We typically employ a short-acting opioid (eg, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a>) for bolus dosing during general anesthesia or MAC. <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil</a> is most suitable for continuous infusion during a total intravenous anesthesia (TIVA) technique, particularly when the intensity of surgical stimulation will vary during the procedure. For postoperative analgesia, we typically administer a long-acting opioid (eg, <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> or <a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">hydromorphone</a>) approximately 20 to 30 minutes before anticipated tracheal extubation, with dose reduction if non-opioid analgesic agents or techniques are coadministered. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients who use opioids chronically may develop tolerance, withdrawal symptoms, <span class=\"nowrap\">and/or</span> opioid-induced hyperalgesia, which may necessitate use of higher opioid doses or alternative agents or techniques to provide analgesia in the perioperative period. (See <a href=\"#H4121615153\" class=\"local\">'Chronic opioid use'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with acute opioid intoxication may have increased risk for opioid adverse effects and opioid tolerance, as well as difficulties with control of postoperative pain. Perioperative analgesic management with nonopioid techniques and agents is employed when possible. (See <a href=\"#H2933998852\" class=\"local\">'Acute opioid intoxication'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/1\" class=\"nounderline abstract_t\">Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology 1991; 74:53.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/2\" class=\"nounderline abstract_t\">Manyam SC, Gupta DK, Johnson KB, et al. Opioid-volatile anesthetic synergy: a response surface model with remifentanil and sevoflurane as prototypes. Anesthesiology 2006; 105:267.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/3\" class=\"nounderline abstract_t\">Hendrickx JF, Eger EI 2nd, Sonner JM, Shafer SL. Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility. Anesth Analg 2008; 107:494.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/4\" class=\"nounderline abstract_t\">Kazama T, Ikeda K, Morita K. The pharmacodynamic interaction between propofol and fentanyl with respect to the suppression of somatic or hemodynamic responses to skin incision, peritoneum incision, and abdominal wall retraction. Anesthesiology 1998; 89:894.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/5\" class=\"nounderline abstract_t\">Smith C, McEwan AI, Jhaveri R, et al. The interaction of fentanyl on the Cp50 of propofol for loss of consciousness and skin incision. Anesthesiology 1994; 81:820.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/6\" class=\"nounderline abstract_t\">Short TG, Plummer JL, Chui PT. Hypnotic and anaesthetic interactions between midazolam, propofol and alfentanil. Br J Anaesth 1992; 69:162.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/7\" class=\"nounderline abstract_t\">Kazama T, Ikeda K, Morita K. Reduction by fentanyl of the Cp50 values of propofol and hemodynamic responses to various noxious stimuli. Anesthesiology 1997; 87:213.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/8\" class=\"nounderline abstract_t\">Van Aken H, Meinshausen E, Prien T, et al. The influence of fentanyl and tracheal intubation on the hemodynamic effects of anesthesia induction with propofol/N2O in humans. Anesthesiology 1988; 68:157.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/9\" class=\"nounderline abstract_t\">Lang E, Kapila A, Shlugman D, et al. Reduction of isoflurane minimal alveolar concentration by remifentanil. Anesthesiology 1996; 85:721.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/10\" class=\"nounderline abstract_t\">Glass PS, Gan TJ, Howell S, Ginsberg B. Drug interactions: volatile anesthetics and opioids. J Clin Anesth 1997; 9:18S.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/11\" class=\"nounderline abstract_t\">Mertens MJ, Olofsen E, Engbers FH, et al. Propofol reduces perioperative remifentanil requirements in a synergistic manner: response surface modeling of perioperative remifentanil-propofol interactions. Anesthesiology 2003; 99:347.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/12\" class=\"nounderline abstract_t\">Chung KS, Sinatra RS, Halevy JD, et al. A comparison of fentanyl, esmolol, and their combination for blunting the haemodynamic responses during rapid-sequence induction. Can J Anaesth 1992; 39:774.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/13\" class=\"nounderline abstract_t\">Cork RC, Weiss JL, Hameroff SR, Bentley J. Fentanyl preloading for rapid-sequence induction of anesthesia. Anesth Analg 1984; 63:60.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/14\" class=\"nounderline abstract_t\">Pouraghaei M, Moharamzadeh P, Soleimanpour H, et al. Comparison between the effects of alfentanil, fentanyl and sufentanil on hemodynamic indices during rapid sequence intubation in the emergency department. Anesth Pain Med 2014; 4:e14618.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/15\" class=\"nounderline abstract_t\">Casati A, Fanelli G, Albertin A, et al. Small doses of remifentanil or sufentanil for blunting cardiovascular changes induced by tracheal intubation: a double-blind comparison. Eur J Anaesthesiol 2001; 18:108.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/16\" class=\"nounderline abstract_t\">O'Hare R, McAtamney D, Mirakhur RK, et al. Bolus dose remifentanil for control of haemodynamic response to tracheal intubation during rapid sequence induction of anaesthesia. Br J Anaesth 1999; 82:283.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/17\" class=\"nounderline abstract_t\">Dahlgren N, Messeter K. Treatment of stress response to laryngoscopy and intubation with fentanyl. Anaesthesia 1981; 36:1022.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/18\" class=\"nounderline abstract_t\">Kelly HE, Shaw GM, Brett CN, et al. The effect of titrated fentanyl on suppressed cough reflex in healthy adult volunteers. Anaesthesia 2016; 71:529.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/19\" class=\"nounderline abstract_t\">Johnston KD, Rai MR. Conscious sedation for awake fibreoptic intubation: a review of the literature. Can J Anaesth 2013; 60:584.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/20\" class=\"nounderline abstract_t\">Zhang X, He W, Wu X, et al. TCI remifentanil vs. TCI propofol for awake fiber-optic intubation with limited topical anesthesia. Int J Clin Pharmacol Ther 2012; 50:10.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/21\" class=\"nounderline abstract_t\">El-Radaideh KM. [Effect of pretreatment with lidocaine, intravenous paracetamol and lidocaine-fentanyl on propofol injection pain. Comparative study. Rev Bras Anestesiol 2007; 57:32.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/22\" class=\"nounderline abstract_t\">Aouad MT, Siddik-Sayyid SM, Al-Alami AA, Baraka AS. Multimodal analgesia to prevent propofol-induced pain: pretreatment with remifentanil and lidocaine versus remifentanil or lidocaine alone. Anesth Analg 2007; 104:1540.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/23\" class=\"nounderline abstract_t\">Rahman Al-Refai A, Al-Mujadi H, Petrova Ivanova M, et al. Prevention of pain on injection of propofol: a comparison of remifentanil with alfentanil in children. Minerva Anestesiol 2007; 73:219.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/24\" class=\"nounderline abstract_t\">Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain 2002; 3:159.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/25\" class=\"nounderline abstract_t\">Zhao SZ, Chung F, Hanna DB, et al. Dose-response relationship between opioid use and adverse effects after ambulatory surgery. J Pain Symptom Manage 2004; 28:35.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/26\" class=\"nounderline abstract_t\">Oderda GM, Said Q, Evans RS, et al. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother 2007; 41:400.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/27\" class=\"nounderline abstract_t\">Oderda GM, Gan TJ, Johnson BH, Robinson SB. Effect of opioid-related adverse events on outcomes in selected surgical patients. J Pain Palliat Care Pharmacother 2013; 27:62.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/28\" class=\"nounderline abstract_t\">Overdyk FJ, Dowling O, Marino J, et al. Association of Opioids and Sedatives with Increased Risk of In-Hospital Cardiopulmonary Arrest from an Administrative Database. PLoS One 2016; 11:e0150214.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/29\" class=\"nounderline abstract_t\">Miller TE, Thacker JK, White WD, et al. Reduced length of hospital stay in colorectal surgery after implementation of an enhanced recovery protocol. Anesth Analg 2014; 118:1052.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/30\" class=\"nounderline abstract_t\">Eskicioglu C, Forbes SS, Aarts MA, et al. Enhanced recovery after surgery (ERAS) programs for patients having colorectal surgery: a meta-analysis of randomized trials. J Gastrointest Surg 2009; 13:2321.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/31\" class=\"nounderline abstract_t\">Varadhan KK, Lobo DN, Ljungqvist O. Enhanced recovery after surgery: the future of improving surgical care. Crit Care Clin 2010; 26:527.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/32\" class=\"nounderline abstract_t\">Feldheiser A, Aziz O, Baldini G, et al. Enhanced Recovery After Surgery (ERAS) for gastrointestinal surgery, part 2: consensus statement for anaesthesia practice. Acta Anaesthesiol Scand 2016; 60:289.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/33\" class=\"nounderline abstract_t\">Brandal D, Keller MS, Lee C, et al. Impact of Enhanced Recovery After Surgery and Opioid-Free Anesthesia on Opioid Prescriptions at Discharge From the Hospital: A Historical-Prospective Study. Anesth Analg 2017; 125:1784.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/34\" class=\"nounderline abstract_t\">Kumar K, Kirksey MA, Duong S, Wu CL. A Review of Opioid-Sparing Modalities in Perioperative Pain Management: Methods to Decrease Opioid Use Postoperatively. Anesth Analg 2017; 125:1749.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/35\" class=\"nounderline abstract_t\">Wick EC, Grant MC, Wu CL. Postoperative Multimodal Analgesia Pain Management With Nonopioid Analgesics and Techniques: A Review. JAMA Surg 2017; 152:691.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/36\" class=\"nounderline abstract_t\">Mitrovic I, Margeta-Mitrovic M, Bader S, et al. Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha 2-adrenergic analgesia and analgesic sex differences. Proc Natl Acad Sci U S A 2003; 100:271.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/37\" class=\"nounderline abstract_t\">De Kock M, Crochet B, Morimont C, Scholtes JL. Intravenous or epidural clonidine for intra- and postoperative analgesia. Anesthesiology 1993; 79:525.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/38\" class=\"nounderline abstract_t\">Gelineau AM, King MR, Ladha KS, et al. Intraoperative Esmolol as an Adjunct for Perioperative Opioid and Postoperative Pain Reduction: A Systematic Review, Meta-analysis, and Meta-regression. Anesth Analg 2018; 126:1035.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/39\" class=\"nounderline abstract_t\">Shapiro A, Zohar E, Zaslansky R, et al. The frequency and timing of respiratory depression in 1524 postoperative patients treated with systemic or neuraxial morphine. J Clin Anesth 2005; 17:537.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/40\" class=\"nounderline abstract_t\">Cashman JN, Dolin SJ. Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth 2004; 93:212.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/41\" class=\"nounderline abstract_t\">Overdyk FJ, Carter R, Maddox RR, et al. Continuous oximetry/capnometry monitoring reveals frequent desaturation and bradypnea during patient-controlled analgesia. Anesth Analg 2007; 105:412.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/42\" class=\"nounderline abstract_t\">Sun Z, Sessler DI, Dalton JE, et al. Postoperative Hypoxemia Is Common and Persistent: A Prospective Blinded Observational Study. Anesth Analg 2015; 121:709.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/43\" class=\"nounderline abstract_t\">Belcher AW, Khanna AK, Leung S, et al. Long-Acting Patient-Controlled Opioids Are Not Associated With More Postoperative Hypoxemia Than Short-Acting Patient-Controlled Opioids After Noncardiac Surgery: A Cohort Analysis. Anesth Analg 2016; 123:1471.</a></li><li class=\"breakAll\">Stoelting R, Miller RD. Opioids. In: Basics of Anesthesia, 5th ed, Elsevier, Philadelphia 2007.</li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/45\" class=\"nounderline abstract_t\">Liu W, Bidwai AV, Stanley TH, Isern-Amaral J. Cardiovascular dynamics after large doses of fentanyl and fentanyl plus N2O in the dog. Anesth Analg 1976; 55:168.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/46\" class=\"nounderline abstract_t\">Prakash O, Verdouw PD, de Jong JW, et al. Haemodynamic and biochemical variables after induction of anaesthesia with fentanyl and nitrous oxide in patients undergoing coronary artery by-pass surgery. Can Anaesth Soc J 1980; 27:223.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/47\" class=\"nounderline abstract_t\">DeSouza G, Lewis MC, TerRiet MF. Severe bradycardia after remifentanil. Anesthesiology 1997; 87:1019.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/48\" class=\"nounderline abstract_t\">Coruh B, Tonelli MR, Park DR. Fentanyl-induced chest wall rigidity. Chest 2013; 143:1145.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/49\" class=\"nounderline abstract_t\">Gravlee GP, Ramsey FM, Roy RC, et al. Rapid administration of a narcotic and neuromuscular blocker: a hemodynamic comparison of fentanyl, sufentanil, pancuronium, and vecuronium. Anesth Analg 1988; 67:39.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/50\" class=\"nounderline abstract_t\">Bennett JA, Abrams JT, Van Riper DF, Horrow JC. Difficult or impossible ventilation after sufentanil-induced anesthesia is caused primarily by vocal cord closure. Anesthesiology 1997; 87:1070.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/51\" class=\"nounderline abstract_t\">Philbin DM, Rosow CE, Schneider RC, et al. Fentanyl and sufentanil anesthesia revisited: how much is enough? Anesthesiology 1990; 73:5.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/52\" class=\"nounderline abstract_t\">Afshan G. Are we anesthesiologists, aware about the incidence of muscle stiffness associated with remifentanil? Anesth Pain Med 2012; 1:218.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/53\" class=\"nounderline abstract_t\">Honda T, Takenami T, Itou N, et al. [Increased dose of remifentanil caused difficult ventilation at emergence from general anesthesia]. Masui 2009; 58:980.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/54\" class=\"nounderline abstract_t\">Kashimoto S, Iijma T, Amemiya M. [Case of muscle rigidity by remifentanil just before the end of surgery]. Masui 2009; 58:984.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/55\" class=\"nounderline abstract_t\">Zhao YJ, Liu S, Mao QX, et al. Efficacy and safety of remifentanil and sulfentanyl in painless gastroscopic examination: a prospective study. Surg Laparosc Endosc Percutan Tech 2015; 25:e57.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/56\" class=\"nounderline abstract_t\">Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014; 118:85.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/57\" class=\"nounderline abstract_t\">Waxler B, Dadabhoy ZP, Stojiljkovic L, Rabito SF. Primer of postoperative pruritus for anesthesiologists. Anesthesiology 2005; 103:168.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/58\" class=\"nounderline abstract_t\">Tarcatu D, Tamasdan C, Moryl N, Obbens E. Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. J Opioid Manag 2007; 3:167.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/59\" class=\"nounderline abstract_t\">Jannuzzi RG. Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature. Clin J Pain 2016; 32:87.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/60\" class=\"nounderline abstract_t\">Hayhurst CJ, Durieux ME. Differential Opioid Tolerance and Opioid-induced Hyperalgesia: A Clinical Reality. Anesthesiology 2016; 124:483.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/61\" class=\"nounderline abstract_t\">Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14:145.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/62\" class=\"nounderline abstract_t\">Ramasubbu C, Gupta A. Pharmacological treatment of opioid-induced hyperalgesia: a review of the evidence. J Pain Palliat Care Pharmacother 2011; 25:219.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/63\" class=\"nounderline abstract_t\">Weber L, Yeomans DC, Tzabazis A. Opioid-induced hyperalgesia in clinical anesthesia practice: what has remained from theoretical concepts and experimental studies? Curr Opin Anaesthesiol 2017; 30:458.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/64\" class=\"nounderline abstract_t\">Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000; 93:409.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/65\" class=\"nounderline abstract_t\">Yu EH, Tran DH, Lam SW, Irwin MG. Remifentanil tolerance and hyperalgesia: short-term gain, long-term pain? Anaesthesia 2016; 71:1347.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/66\" class=\"nounderline abstract_t\">Angst MS. Intraoperative Use of Remifentanil for TIVA: Postoperative Pain, Acute Tolerance, and Opioid-Induced Hyperalgesia. J Cardiothorac Vasc Anesth 2015; 29 Suppl 1:S16.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/67\" class=\"nounderline abstract_t\">Kharasch ED, Brunt LM. Perioperative Opioids and Public Health. Anesthesiology 2016; 124:960.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/68\" class=\"nounderline abstract_t\">Hah JM, Bateman BT, Ratliff J, et al. Chronic Opioid Use After Surgery: Implications for Perioperative Management in the Face of the Opioid Epidemic. Anesth Analg 2017; 125:1733.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/69\" class=\"nounderline abstract_t\">Picard P, Tram&egrave;r MR. Prevention of pain on injection with propofol: a quantitative systematic review. Anesth Analg 2000; 90:963.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/70\" class=\"nounderline abstract_t\">Prabhakar H, Singh GP, Ali Z, et al. Pharmacological and non-pharmacological interventions for reducing rocuronium bromide induced pain on injection in children and adults. Cochrane Database Syst Rev 2016; 2:CD009346.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/71\" class=\"nounderline abstract_t\">Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992; 76:334.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/72\" class=\"nounderline abstract_t\">Miller TE, Gan TJ. Total intravenous anesthesia and anesthetic outcomes. J Cardiothorac Vasc Anesth 2015; 29 Suppl 1:S11.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/73\" class=\"nounderline abstract_t\">Kim JE, Min SK, Chae YJ, et al. Pharmacological and nonpharmacological prevention of fentanyl-induced cough: a meta-analysis. J Anesth 2014; 28:257.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/74\" class=\"nounderline abstract_t\">Uvelin A, Rakic G. Guidelines for prevention of fentanyl-induced cough. Acta Anaesthesiol Scand 2009; 53:1228.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/75\" class=\"nounderline abstract_t\">Levin TT, Bakr MH, Nikolova T. Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction. Gen Hosp Psychiatry 2010; 32:648.e9.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/76\" class=\"nounderline abstract_t\">Cambic CR, Avram MJ, Gupta DK, Wong CA. Effect of ritonavir-induced cytochrome P450 3A4 inhibition on plasma fentanyl concentrations during patient-controlled epidural labor analgesia: a pharmacokinetic simulation. Int J Obstet Anesth 2014; 23:45.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/77\" class=\"nounderline abstract_t\">Bj&ouml;rkman S, Stanski DR, Harashima H, et al. Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model. J Pharmacokinet Biopharm 1993; 21:255.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/78\" class=\"nounderline abstract_t\">Gelberg J, Jonmarker C, Stenqvist O, Werner O. Intravenous boluses of fentanyl, 1 &mu;g kg&#8315;&sup1;, and remifentanil, 0.5 &mu;g kg&#8315;&sup1;, give similar maximum ventilatory depression in awake volunteers. Br J Anaesth 2012; 108:1028.</a></li><li class=\"breakAll\">Johnson KB, Healy A. The clinical pharmacology of opioids. In: Clinical Pharmacology for Anesthesiology, McGraw-Hill, New York 2014.</li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/80\" class=\"nounderline abstract_t\">Beers R, Camporesi E. Remifentanil update: clinical science and utility. CNS Drugs 2004; 18:1085.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/81\" class=\"nounderline abstract_t\">Klemola UM, Mennander S, Saarnivaara L. Tracheal intubation without the use of muscle relaxants: remifentanil or alfentanil in combination with propofol. Acta Anaesthesiol Scand 2000; 44:465.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/82\" class=\"nounderline abstract_t\">Bouvet L, Stoian A, Rimmel&eacute; T, et al. Optimal remifentanil dosage for providing excellent intubating conditions when co-administered with a single standard dose of propofol. Anaesthesia 2009; 64:719.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/83\" class=\"nounderline abstract_t\">Trabold F, Casetta M, Duranteau J, et al. Propofol and remifentanil for intubation without muscle relaxant: the effect of the order of injection. Acta Anaesthesiol Scand 2004; 48:35.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/84\" class=\"nounderline abstract_t\">Berger M, Philips-Bute B, Guercio J, et al. A novel application for bolus remifentanil: blunting the hemodynamic response to Mayfield skull clamp placement. Curr Med Res Opin 2014; 30:243.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/85\" class=\"nounderline abstract_t\">Joshi GP, Jamerson BD, Roizen MF, et al. Is there a learning curve associated with the use of remifentanil? Anesth Analg 2000; 91:1049.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/86\" class=\"nounderline abstract_t\">Sajedi P, Rahimian A, Khalili G. Comparative evaluation between two methods of induced hypotension with infusion of Remifentanil and Labetalol during sinus endoscopy. J Res Pharm Pract 2016; 5:264.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/87\" class=\"nounderline abstract_t\">Echevarr&iacute;a G, Elgueta F, Fierro C, et al. Nitrous oxide (N(2)O) reduces postoperative opioid-induced hyperalgesia after remifentanil-propofol anaesthesia in humans. Br J Anaesth 2011; 107:959.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/88\" class=\"nounderline abstract_t\">Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005; 103:147.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/89\" class=\"nounderline abstract_t\">Hoshijima H, Takeuchi R, Kuratani N, et al. Incidence of postoperative shivering comparing remifentanil with other opioids: a meta-analysis. J Clin Anesth 2016; 32:300.</a></li><li class=\"breakAll\">Ultiva [package insert]. Canonsburg, PA: Mylan; 2015.</li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/91\" class=\"nounderline abstract_t\">Halliburton JR. The pharmacokinetics of fentanyl, sufentanil and alfentanil: a comparative review. AANA J 1988; 56:229.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/92\" class=\"nounderline abstract_t\">Maciejewski D. Sufentanil in anaesthesiology and intensive therapy. Anaesthesiol Intensive Ther 2012; 44:35.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/93\" class=\"nounderline abstract_t\">Djian MC, Blanchet B, Pesce F, et al. Comparison of the time to extubation after use of remifentanil or sufentanil in combination with propofol as anesthesia in adults undergoing nonemergency intracranial surgery: a prospective, randomized, double-blind trial. Clin Ther 2006; 28:560.</a></li><li class=\"breakAll\">Sufentanil Citrate [package insert]. Lake Forest, IL: Hospira; 2014.</li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/95\" class=\"nounderline abstract_t\">L&ouml;tsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005; 29:S90.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/96\" class=\"nounderline abstract_t\">Saari TI, Laine K, Leino K, et al. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther 2006; 80:502.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/97\" class=\"nounderline abstract_t\">MacKenzie M, Zed PJ, Ensom MH. Opioid Pharmacokinetics-Pharmacodynamics: Clinical Implications in Acute Pain Management in Trauma. Ann Pharmacother 2016; 50:209.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/98\" class=\"nounderline abstract_t\">Felden L, Walter C, Harder S, et al. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. Br J Anaesth 2011; 107:319.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/99\" class=\"nounderline abstract_t\">Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001; 9:84.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/100\" class=\"nounderline abstract_t\">Jeleazcov C, Saari TI, Ihmsen H, et al. Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. Anesthesiology 2014; 120:378.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/101\" class=\"nounderline abstract_t\">Davison SN, Mayo PR. Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. J Opioid Manag 2008; 4:335.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/102\" class=\"nounderline abstract_t\">Palmer PP, Royal MA, Miller RD. Novel delivery systems for postoperative analgesia. Best Pract Res Clin Anaesthesiol 2014; 28:81.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/103\" class=\"nounderline abstract_t\">Jain AK, Kumar S, Tyagi A. Practice trends in use of morphine for control of intraoperative pain: An audit. J Anaesthesiol Clin Pharmacol 2012; 28:62.</a></li><li class=\"breakAll\">Morphine Sulfate [package insert]. Lake Forest, IL: Hospira; 2011.</li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/105\" class=\"nounderline abstract_t\">Aubrun F, Amour J, Rosenthal D, et al. Effects of a loading dose of morphine before i.v. morphine titration for postoperative pain relief: a randomized, double-blind, placebo-control study. Br J Anaesth 2007; 98:124.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/106\" class=\"nounderline abstract_t\">Aubrun F, Mazoit JX, Riou B. Postoperative intravenous morphine titration. Br J Anaesth 2012; 108:193.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/107\" class=\"nounderline abstract_t\">Peterson GM, Randall CT, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 1990; 38:121.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/108\" class=\"nounderline abstract_t\">Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251:477.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/109\" class=\"nounderline abstract_t\">Vadivelu N, Mitra S, Kaye AD, Urman RD. Perioperative analgesia and challenges in the drug-addicted and drug-dependent patient. Best Pract Res Clin Anaesthesiol 2014; 28:91.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/110\" class=\"nounderline abstract_t\">Pulley DD. Preoperative Evaluation of the Patient with Substance Use Disorder and Perioperative Considerations. Anesthesiol Clin 2016; 34:201.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/111\" class=\"nounderline abstract_t\">Bryson EO. The perioperative management of patients maintained on medications used to manage opioid addiction. Curr Opin Anaesthesiol 2014; 27:359.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/112\" class=\"nounderline abstract_t\">Cammarano WB, Pittet JF, Weitz S, et al. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med 1998; 26:676.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/113\" class=\"nounderline abstract_t\">Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003; 35:253.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/114\" class=\"nounderline abstract_t\">Tompkins DA, Bigelow GE, Harrison JA, et al. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend 2009; 105:154.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/115\" class=\"nounderline abstract_t\">Stromer W, Michaeli K, Sandner-Kiesling A. Perioperative pain therapy in opioid abuse. Eur J Anaesthesiol 2013; 30:55.</a></li><li><a href=\"https://www.uptodate.com/contents/perioperative-uses-of-intravenous-opioids-in-adults/abstract/116\" class=\"nounderline abstract_t\">Honey BL, Benefield RJ, Miller JL, Johnson PN. Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Ann Pharmacother 2009; 43:1506.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 94536 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H2730096515\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1944728715\" id=\"outline-link-H1944728715\">INTRODUCTION</a></li><li><a href=\"#H2754072954\" id=\"outline-link-H2754072954\">BENEFITS</a></li><li><a href=\"#H4025963507\" id=\"outline-link-H4025963507\">PREVENTION AND MANAGEMENT OF ADVERSE EFFECTS</a></li><li><a href=\"#H153801862\" id=\"outline-link-H153801862\">DOSING CONSIDERATIONS</a></li><li><a href=\"#H1495146211\" id=\"outline-link-H1495146211\">PERIOPERATIVE USES</a><ul><li><a href=\"#H3970381375\" id=\"outline-link-H3970381375\">General anesthesia</a><ul><li><a href=\"#H722402749\" id=\"outline-link-H722402749\">- Preinduction</a></li><li><a href=\"#H2978013286\" id=\"outline-link-H2978013286\">- Induction</a><ul><li><a href=\"#H1224100467\" id=\"outline-link-H1224100467\">Opioid use as an adjuvant agent</a></li><li><a href=\"#H1812591377\" id=\"outline-link-H1812591377\">High-dose opioid induction technique</a></li></ul></li><li><a href=\"#H2897922683\" id=\"outline-link-H2897922683\">- Maintenance</a></li><li><a href=\"#H3912015127\" id=\"outline-link-H3912015127\">- Emergence</a></li></ul></li><li><a href=\"#H3696324081\" id=\"outline-link-H3696324081\">Monitored anesthesia care</a></li><li><a href=\"#H177868102\" id=\"outline-link-H177868102\">Treatment of acute postoperative pain</a></li></ul></li><li><a href=\"#H3190470157\" id=\"outline-link-H3190470157\">FENTANYL</a><ul><li><a href=\"#H985440738\" id=\"outline-link-H985440738\">Uses and dosing</a><ul><li><a href=\"#H1364249633\" id=\"outline-link-H1364249633\">- General anesthesia</a></li><li><a href=\"#H3922967017\" id=\"outline-link-H3922967017\">- Monitored anesthesia care</a></li><li><a href=\"#H1394704132\" id=\"outline-link-H1394704132\">- Treatment of acute postoperative pain</a></li></ul></li><li><a href=\"#H3929588360\" id=\"outline-link-H3929588360\">Advantages</a></li><li><a href=\"#H2463920111\" id=\"outline-link-H2463920111\">Disadvantages</a></li><li><a href=\"#H1280607721\" id=\"outline-link-H1280607721\">Drug-drug interactions</a></li><li><a href=\"#H897171228\" id=\"outline-link-H897171228\">Pharmacokinetics</a></li></ul></li><li><a href=\"#H4265539633\" id=\"outline-link-H4265539633\">REMIFENTANIL</a><ul><li><a href=\"#H2617550523\" id=\"outline-link-H2617550523\">Uses and dosing</a><ul><li><a href=\"#H1979952751\" id=\"outline-link-H1979952751\">- General anesthesia</a></li><li><a href=\"#H4261605709\" id=\"outline-link-H4261605709\">- Monitored anesthesia care</a></li></ul></li><li><a href=\"#H1558056750\" id=\"outline-link-H1558056750\">Advantages</a></li><li><a href=\"#H125978762\" id=\"outline-link-H125978762\">Disadvantages</a></li><li><a href=\"#H1011953393\" id=\"outline-link-H1011953393\">Drug-drug interactions</a></li><li><a href=\"#H906498990\" id=\"outline-link-H906498990\">Pharmacokinetics</a></li></ul></li><li><a href=\"#H4176363563\" id=\"outline-link-H4176363563\">SUFENTANIL</a><ul><li><a href=\"#H2867551102\" id=\"outline-link-H2867551102\">Uses and dosing</a><ul><li><a href=\"#H3166497392\" id=\"outline-link-H3166497392\">- General anesthesia</a></li></ul></li><li><a href=\"#H4127321796\" id=\"outline-link-H4127321796\">Advantages</a></li><li><a href=\"#H1241061197\" id=\"outline-link-H1241061197\">Disadvantages</a></li><li><a href=\"#H3219764222\" id=\"outline-link-H3219764222\">Drug-drug interactions</a></li><li><a href=\"#H3794233678\" id=\"outline-link-H3794233678\">Pharmacokinetics</a></li></ul></li><li><a href=\"#H4207798916\" id=\"outline-link-H4207798916\">ALFENTANIL</a><ul><li><a href=\"#H1206610327\" id=\"outline-link-H1206610327\">Uses and dosing</a><ul><li><a href=\"#H575561191\" id=\"outline-link-H575561191\">- General anesthesia</a></li></ul></li><li><a href=\"#H1196586843\" id=\"outline-link-H1196586843\">Advantages</a></li><li><a href=\"#H4263926894\" id=\"outline-link-H4263926894\">Disadvantages</a></li><li><a href=\"#H2682376348\" id=\"outline-link-H2682376348\">Drug-drug interactions</a></li><li><a href=\"#H1538695758\" id=\"outline-link-H1538695758\">Pharmacokinetics</a></li></ul></li><li><a href=\"#H2455208050\" id=\"outline-link-H2455208050\">HYDROMORPHONE</a><ul><li><a href=\"#H3630954278\" id=\"outline-link-H3630954278\">Uses and dosing</a><ul><li><a href=\"#H189190759\" id=\"outline-link-H189190759\">- General anesthesia</a></li><li><a href=\"#H2677374416\" id=\"outline-link-H2677374416\">- Treatment of acute postoperative pain</a></li></ul></li><li><a href=\"#H2870541\" id=\"outline-link-H2870541\">Advantages</a></li><li><a href=\"#H453525651\" id=\"outline-link-H453525651\">Disadvantages</a></li><li><a href=\"#H908188094\" id=\"outline-link-H908188094\">Drug-drug interactions</a></li><li><a href=\"#H2151248242\" id=\"outline-link-H2151248242\">Pharmacokinetics</a></li></ul></li><li><a href=\"#H3027426084\" id=\"outline-link-H3027426084\">MORPHINE</a><ul><li><a href=\"#H1589351287\" id=\"outline-link-H1589351287\">Uses and dosing</a><ul><li><a href=\"#H111566137\" id=\"outline-link-H111566137\">- General anesthesia</a></li><li><a href=\"#H2163730101\" id=\"outline-link-H2163730101\">- Treatment of acute postoperative pain</a></li></ul></li><li><a href=\"#H1272516313\" id=\"outline-link-H1272516313\">Advantages</a></li><li><a href=\"#H219866222\" id=\"outline-link-H219866222\">Disadvantages</a></li><li><a href=\"#H2396470625\" id=\"outline-link-H2396470625\">Drug-drug interactions</a></li><li><a href=\"#H3279440888\" id=\"outline-link-H3279440888\">Pharmacokinetics</a></li></ul></li><li><a href=\"#H3721078605\" id=\"outline-link-H3721078605\">CHRONIC OR ACUTE OPIOID USE/ABUSE</a><ul><li><a href=\"#H4121615153\" id=\"outline-link-H4121615153\">Chronic opioid use</a></li><li><a href=\"#H2933998852\" id=\"outline-link-H2933998852\">Acute opioid intoxication</a></li></ul></li><li><a href=\"#H2730096515\" id=\"outline-link-H2730096515\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ANEST/94536|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ANEST/109502\" class=\"graphic graphic_figure\">- Context-sensitive half time for opioids</a></li><li><a href=\"image.htm?imageKey=ANEST/109504\" class=\"graphic graphic_figure\">- Bolus front-end and back-end pharmacokinetics of opioids</a></li><li><a href=\"image.htm?imageKey=ANEST/109503\" class=\"graphic graphic_figure\">- Rapid attainment of steady state with remifentanil</a></li></ul></li><li><div id=\"ANEST/94536|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ANEST/111779\" class=\"graphic graphic_table\">- Perioperative uses and doses of intravenous opioid agents</a></li><li><a href=\"image.htm?imageKey=EM/64604\" class=\"graphic graphic_table\">- Serotonin syndrome drugs</a></li><li><a href=\"image.htm?imageKey=ANEST/111780\" class=\"graphic graphic_table\">- Pharmacokinetics for IV opioids in the perioperative setting</a></li><li><a href=\"image.htm?imageKey=EM/81045\" class=\"graphic graphic_table\">- Clinical features of opioid withdrawal</a></li><li><a href=\"image.htm?imageKey=PSYCH/106994\" class=\"graphic graphic_table\">- Clinical Opioid Withdrawal Scale (COWS)</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-opioid-intoxication-in-adults\" class=\"medical medical_review\">Acute opioid intoxication in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-coronary-artery-bypass-grafting-surgery\" class=\"medical medical_review\">Anesthesia for coronary artery bypass grafting surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-craniotomy\" class=\"medical medical_review\">Anesthesia for craniotomy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-emergent-eye-surgery\" class=\"medical medical_review\">Anesthesia for emergent eye surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-the-patient-on-dialysis\" class=\"medical medical_review\">Anesthesia for the patient on dialysis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=arrhythmias-during-anesthesia\" class=\"medical medical_review\">Arrhythmias during anesthesia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=delayed-emergence-and-emergence-delirium-in-adults\" class=\"medical medical_review\">Delayed emergence and emergence delirium in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=flexible-scope-intubation-for-anesthesia\" class=\"medical medical_review\">Flexible scope intubation for anesthesia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-anesthesia-intravenous-induction-agents\" class=\"medical medical_review\">General anesthesia: Intravenous induction agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-anesthesia-maintenance-and-emergence\" class=\"medical medical_review\">General anesthesia: Maintenance and emergence</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-acute-pain-in-the-patient-chronically-using-opioids\" class=\"medical medical_review\">Management of acute pain in the patient chronically using opioids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-acute-perioperative-pain\" class=\"medical medical_review\">Management of acute perioperative pain</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=monitored-anesthesia-care-in-adults\" class=\"medical medical_review\">Monitored anesthesia care in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=opioid-use-disorder-epidemiology-pharmacology-clinical-manifestations-course-screening-assessment-and-diagnosis\" class=\"medical medical_review\">Opioid use disorder: Epidemiology, pharmacology, clinical manifestations, course, screening, assessment, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=opioid-withdrawal-in-the-emergency-setting\" class=\"medical medical_review\">Opioid withdrawal in the emergency setting</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-post-anesthetic-care-for-adult-patients\" class=\"medical medical_review\">Overview of post-anesthetic care for adult patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pain-assessment-and-management-in-the-last-weeks-of-life\" class=\"medical medical_review\">Pain assessment and management in the last weeks of life</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pain-control-in-the-critically-ill-adult-patient\" class=\"medical medical_review\">Pain control in the critically ill adult patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=postoperative-ileus\" class=\"medical medical_review\">Postoperative ileus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=postoperative-nausea-and-vomiting\" class=\"medical medical_review\">Postoperative nausea and vomiting</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-management-of-side-effects-in-patients-receiving-opioids-for-chronic-pain\" class=\"medical medical_review\">Prevention and management of side effects in patients receiving opioids for chronic pain</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rapid-sequence-induction-and-intubation-rsii-for-anesthesia\" class=\"medical medical_review\">Rapid sequence induction and intubation (RSII) for anesthesia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=respiratory-problems-in-the-post-anesthesia-care-unit-pacu\" class=\"medical medical_review\">Respiratory problems in the post-anesthesia care unit (PACU)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal\" class=\"medical medical_review\">Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=serotonin-syndrome-serotonin-toxicity\" class=\"medical medical_review\">Serotonin syndrome (serotonin toxicity)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-opioids-in-the-management-of-chronic-non-cancer-pain\" class=\"medical medical_review\">Use of opioids in the management of chronic non-cancer pain</a></li></ul></div></div>","javascript":null}